CUMULATIVE INDEX 1998

Volume 45

February	PHYSICAL ASSESSMENT, pages 1–267
April	VIOLENCE AMONG CHILDREN AND ADOLESCENTS, pages 269–474
June	NEONATOLOGY UPDATE, pages 475–717
August	PEDIATRIC SURGERY FOR THE PRIMARY CARE PEDIATRICIAN, PART I, pages 719–1020
October	CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, pages 1021–1286
December	PEDIATRIC SURGERY FOR THE PRIMARY CARE PEDIATRICIAN, PART II, pages 1287–1727

Note: Page numbers of article titles are in **boldface** type.

Abdomen, blunt trauma to, evaluation for physical abuse, 210–211
embryology and anatomy, 729
pain. See *Abdominal diagnoses.*
wounds, suturing, 838
Abdominal diagnoses, **729–772, 1287–1326**
abdominal wall defects, 1343–1344
adhesive small bowel obstruction, 761–762
appendicitis, 733–739
bleeding, 1294–1301
constipation (Hirschsprung's disease), 1287–1294
gallbladder disease, 759–761
hypertrophic pyloric stenosis, 739–746
injuries, 855–858
intussusception, 746–752
lymphadenopathy, 884–885
malrotation and midgut volvulus, 752–759
masses, 1302–1317
pain evaluation in immunosuppressed or neurologically impaired patients, 762–766
presenting characteristics, 730–731
recurrent pain, 1317–1321
visceral, somatic, and referred pain, 732
Abdominal surgery for cancer, complications of, 1638, 1640
Abscesses, deep palmar space, 1523
Absorption of drug, 1022
Abuse. See *Child abuse; Sexual abuse; Substance abuse.*
Academic achievement/performance, in childhood psychiatric disorders, 31–32, 46
in children witnessing violence, 358
media violence and, 327–328
television viewing time and, 326
Acalculous cholecystitis, 760–761
Accidents, among adolescents, 187
Accommodative esotropia, 998–1000
Acetaminophen, 1529
Achilles tendonitis, 238
Acid reflux. See *Gastroesophageal reflux.*
Aciduria, paradoxical, 726
Activities, of adolescents with serious or sensitive issues, 196
in childhood psychiatric disorders, 34–35, 46
Acute respiratory distress syndrome, development of, 575
inhaled nitric oxide for, 539–540
surfactant for, 559–561
Acute stress disorder, 1188
Acute suppurative cervical lymphadenitis, 900–901

ADD Comprehensive Teacher/Parent Rating Scales, 1061
Adderall, 1065, 1070, 1087–1088, 1090
Adenoidectomy, clinical presentation for, 974
  complications, 978
  diagnostic studies before, 975
  evaluation for, 977
  indications, 977–978
Adenomas, hepatic, 1312
ADHD. See *Attention-deficit hyperactivity disorder.*
Adhesive small bowel obstruction, 730, 761–762
Adolescents, antipsychotics in, 1209, 1210
  breast surgery in, 1496–1502
  development of, 189–190
  guidelines for preventive services for, 1686
  idiopathic scoliosis in, 954–957
  organ transplantation in, 1409–1410
  parenthood by, 312–314
  physical examination of, 19–22
  psychostimulants in, 1071–1073
  relationship violence among, prevention of, 444–445
  with serious or sensitive issues, assessment of, approach to, **187–202**
    behavioral factors in, 188
    environment for information collection, 190–194
      body language, 193
      building rapport, 193–194
      confidentiality, 190–192
      interviewing techniques, 193
      privacy, 192–193
    psychosocial interview with, 194–199
      activities, 196
      drugs, 196–198
      education/employment, 195–196
      home, 194–195
      sexuality, 198–199
      suicide, 199
    thought provoking questions for, 199–200
  sexually transmitted disease in, 312–314, 1684–1685
  sports injuries in, **1601–1635**
  suicide in, 187, **365–380,** 421
  violence against, international perspectives on, **415–426**
  violence in, 276–277
    and associated high-risk health behavior, **307–317**
    prevention strategies for, 443–447
Adrenergic agonists. See *Alpha–2 adrenergic agonists.*
Adrenergic antidepressants, novel, 1168
Affect, regulation of, with exposure to violence, 344
Aganglionosis, congenital intestinal. See *Hirschsprung's disease.*
Age, side effects of psychotropic drugs and, 1028
Aggression, antipsychotics in, 1214
  as consequence of media violence, 325–326, 328
  in mentally retarded patients, mood stabilizers in, 1182–1183
Air leak syndromes, with ventilation, in acute respiratory failure in newborns, 491–492
Albuterol, 1267
Alcohol abuse, 1041
Alcoholism, in adolescent suicide, 369–370
Alcohol use, in adolescents, 307–308
    relationship to other behaviors, 308–309
    risk factors for, 308
    violence prevention strategies with, 444
  as consequence of media violence, 327
Alertness, definition of, 138
Alimentary tract duplications, 1300
Allen test, 1391, 1510–1511
Allergic dermatitis, with intestinal ostomies, 1432
Alpha–2 adrenergic agonists, **1099–1122**
  clinical efficacy of, in anxiety disorders and post-traumatic stress disorder, 1109
    in attention-deficit and disruptive behavior disorder, 1109–1112
    in pervasive developmental disorders, 1112
    in Tourette's disorder, 1112
  clinical use of, adverse effects, 1115–1116
    cases, 1117–1118
    dosing, 1115
    guidelines, 1112–1114
    medical work-up, 1116
    properties of drugs, 1114–1115
    sudden death on combined clonidine-methylphenidate treatment, 1116–1117
  historical perspective, 1099, 1100
  neurochemistry and neurophysiology, arousal, stress, and locus coeruleus function, 1101
    basic properties of α_2 adrenoreceptor, 1100–1101
    in specific disorders, 1101–1109
Alpha–2 adrenoreceptor, basic properties of, 1100–1101
  dysfunction, anxiety disorders and, 1101–1102
    attention-deficit hyperactivity disorder and, 1102–1103
    in Tourette's syndrome and tic disorders, 1103, 1108–1109

Alpha-fetoprotein, in liver tumors, 1316
Alprazolam, in anxiety disorders, 1197–1198
  drug interactions with, 1241, 1255
Alveolar reconstruction, in cleft lip and palate, 1494–1495
Amantadine, 1220
Amblyopia, 994
Amelogenesis imperfecta, 1584
Amenorrhea, 1648
  primary, congenital anomalies presenting as, 1674
  secondary, 1679
Amethocaine, in dermatologic surgery, 1439
Amineptine, 1167
Amitriptyline, 1125. See also *Antidepressants, tricyclic.*
Amnioinfusion, for meconium-stained amniotic fluid, 517
Amniotic fluid, meconium-stained, **511–529**
  amnioinfusion for, 517
  brain injury with, 524
  demography, 511–512
  neonatal outcome with, 516–517
  pathophysiology, 512–515
  toxicity with, 515–516
Amphetamine salts, mixture of (Adderall), 1065, 1070, 1087–1088, 1090
Ampicillin, 1267
Amputations, digital, traumatic, 1521
Anal fissures, 1300, 1366
Analgesia, 1529, 1532–1534
Androgen skin patches, 1672
Anesthesia, **1525–1537**
  complications and precautions, 1530–1532
  for dermatologic surgery, 1438–1439
  fluid and electrolyte management and, 1530
  general, 1527–1529
  in hand disorders, 1512–1515
  in mild injuries, 836–837
  outside operating room, 1535
  pain management, 1532–1534
  postanesthesia care unit, 1532
  preoperative issues, 1525–1527
  specific issues, 1535–1536
Angioblastoma of Nakagawa, 1465
Animal bites of hand, 1521–1522
Aniridia, 1005
  Wilms' tumor and, 1308
Ankle, sports injuries to, 235–238, 1629–1632
Anorchidism, 820
Anorectal anatomy, female, 1356
Anorectal bleeding, 1300
Anorectal malformations, 1339–1342. See also *Rectal and perineal problems.*
Anorectal manometry, in Hirschsprung's disease, 1290
Anorexia nervosa, antipsychotics in, 1217
Antegrade continence enema, 1355
Anterior cruciate ligament injuries, 1624, 1625, 1627, 1628
Anterior drawer test, 1630, 1632
Anterior knee pain, 1618–1620
Anthracyclines, complications of, 1642, 1643
Antiangiogenic drug therapy, for hemangiomas, 1467–1468
Antibiotics, for catheter infection, 1390
  in sinusitis, 983
Anticoagulation, valve prostheses and, 916–917
Anticonvulsants. See *Mood stabilizers and anticonvulsants.*
Antidepressants. See also *Selective serotonin reuptake inhibitors.*
  in attention-deficit hyperactivity disorder, 1029, 1076–1077
  classified by mechanism of action, 1159
  future, 1276
  newer/atypical, **1157–1171**
    adrenergic antidepressants, 1168
    augmentation strategies, 1165–1166
    bupropion, 1162
    buspirone, 1163–1164
    combined serotonin and norepinephrine reuptake inhibitors, 1167
    dopamine receptor agonists and antagonists, 1167
    dopaminergic antidepressants, 1167
    drugs affecting dopamine uptake and release, 1167
    minaprine, 1168
    mirtazapine, 1164
    monoamine oxidase inhibitors, 1165, 1168
    nefazodone, 1161
    serotonergic antidepressants, 1166–1167
    trazodone, 1160–1161
    venlafaxine, 1162–1163
  side effects of, 1028
  tricyclic, **1123–1135**
    adverse effects of, 1129–1130, 1195–1196
    clinical indications for, anxiety disorders, 1128–1129, 1190, 1194–1197
      attention-deficit hyperactivity disorder, 1126–1127
      depression, 1030, 1127–1128
      enuresis, 1127
      tic disorders and Tourette syndrome, 1128
    drug interactions with, 1124, 1196–1197, 1238, 1240, 1243, 1244–1247, 1252, 1255

Antidepressants *(Continued)*
pharmacology, 1123–1124, 1126
prescribing and monitoring, 1130–1131
specific drugs, 1125
Antifungals, azole, drug interactions with, 1248, 1254
Antihistamines, in anxiety disorders, 1199
Antimalarials, drug interactions with, 1251
Antimicrobial prophylaxis, in splenectomy, 856
Antipsychotics, **1205–1232**
adverse effects and safety of, 1217, 1218, 1221–1222
extrapyramidal side effects, 1217, 1219–1221
in anorexia nervosa, 1217
atypical, 1206, 1207
in autistic disorder and pervasive developmental disorders, 1214–1215
diagnoses and target symptoms for, 1208
in disruptive behavior disorders, 1214
future, 1276
in mental retardation, 1215–1216
in mood disorders, 1213
in pediatric practice, 1207–1209
in personality disorders, 1216–1217
in schizophrenia, 1209, 1212–1213
studies of, 1210–1211
in tic disorders, 1216
typical, 1206
use of, practical approach to, 1222–1224
Antipyrine, 1267
Antley-Bixier syndrome, 1550
Anus, ectopic, 1356–1358
fissures, 1300, 1366
imperforate, 1353–1356
Anxiety, in children witnessing violence, 358
Anxiety disorders, 1039–1040, 1187
alpha–2 adrenoreceptor dysfunction and, 1101–1102
cormorbid conditions, treatment of, 1200
pharmacologic treatment, **1187–1204**
alpha–2 adrenergic agonists, 1109
benzodiazepines, 1197–1199
miscellaneous, 1199
selection of, 1191
selective serotonin reuptake inhibitors, 1140, 1192–1194
tricyclic antidepressants, 1128–1129, 1194–1197
studies of, 1188–1191
types of, 188
Aorta, coarctation of, 929–930
Aortic area, in cardiac murmur evaluation, 112–113
Aortic systolic cardiac murmur, 116–117
Aortic valve stenosis and bicuspid aortic valve, 930–931
Apert's syndrome, 1549, 1550
APGAR score, in neonatal risk assessment, 654
Aplasia cutis congenita, surgical management, 1446–1447
Apophyseal injuries, 1613, 1615
Appendectomy, 736
Appendicitis, 733
clinical correlation and commentary, 738–739
clinical presentation and evaluation, characteristics, 730
diagnostic studies, 735–736
history, 733–734
physical examination, 734–735
complications, prognosis, and outcome, 737–738
differential diagnosis, 736
epidemiology, 733
fluid therapy in, 726
follow-up guidelines, 738
treatment, 736–737
L-Arginine pathway, of nitric oxide, 533
Arrhythmias, in former cardiac surgery patient, 910–911
supraventricular, 911–912
ventricular, 912–913
Arterial cannulation, 1390–1391
Arterial switch operation, 934–935
Arteriovenous malformations, 1474–1475
Ascorbic acid, deficiency of, 253–254
Aspiration, foreign body, 869
Assault, child and adolescent, 420
Astemizole, drug interactions with, 1241, 1255
Asthma, anesthesia and, 1536
Ataxia, clinical approach to, 148
Ataxia-telangiectasia, 1472
Atrial flutter, 911
Atrial septal defects, 926–927
Atrioventricular septal defects, 933–934
Atrophy, with peripheral nerve weakness, 161
Atropine, drug interactions with, 1245, 1251
in neonatal cardiopulmonary resuscitation, 596
Attendance at school, in childhood psychiatric disorders, 32–33
Attention-deficit hyperactivity disorder, 1038–1039, **1053–1083**
alpha–2 adrenoreceptor dysfunction and, 1102–1103
assessment, behavioral checklist, 1059–1060
information obtained in office visits, 1062–1069
cases, 1046–1049, 1053–1054, 1056, 1057
classification of, 1055–1058

clinical trials of, 1272
comorbid disorders, 1057–1058, 1128
drug treatment, 1029
alpha–2 adrenergic agonists, 1100, 1109–1112
case, 1118
clinical usage, 1112–1114, 1115
antidepressants, 1076–1077, 1126–1127
antipsychotics, 1214
effects and dosing, 1069–1070
future, 1277
psychostimulants, 1067, 1070–1076
reluctance to use medications, 1066
specific medications, 1064–1065
educational placement and, 1078–1079
family and, 1063, 1066–1067
general pediatrician and, 1054–1055
home interventions in, 1079
hyperactive-impulsive, 1056
inattentive, 1057
myths, 1063, 1066–1067
prognosis, 1058, 1067–1068
referrals for, 1079
Autistic disorder, antipsychotics in, 1214–1215
Autoimmune neuropsychiatric disorders, streptococcal infections and, 1031
Autonomy, in risk and resiliency for violence, 294
Avascular necrosis, 1645
Avulsion apophysitis, 1616–1618
Axillary lymphadenopathy, 885
Azole antifungals, drug interactions with, 1248, 1254
Azoospermia, 1647

Back pain, 224, 957–959
Back wounds, suturing, 838
Bacterial infections, in lymphadenopathy, 879–881
Balanitis, 806
Bard button, 1330, 1427–1428
Barium enema, in intussusception, 748–749
Beckwith-Wiedemann syndrome, 1308, 1314
Behavior. See also *Conduct disorder; Disruptive behavior disorders.*
in attention-deficit hyperactivity disorder, checklist of, 1059–1060
Child Behavior Checklist, 1044
history, in severe neurologic impairment, 129
Benign extra-axial fluid collections of infancy, 1544–1548
Benzodiazepines, 1529
in anxiety disorders, 1190, 1197–1199
drug interactions with, 1199, 1244, 1248–1249
side effects and toxicity of, 1198
Benztropine, 1220
Bereaved family, 695–698
Beta-blockers, in anxiety disorders, 1199
Beta 2–receptor antagonists, drug interactions with, 1248
Bicuspid aortic valve, 930–931
Bilateral coronal synostosis, 1549, 1551–1552
Biliary atresia, 1342–1343
neonatal surgery for, 615–616
Binge drinking, 307–308
Biopsy, skin, 1439–1441
Biotin deficiency, 252
Bipolar disorders, 1179
comorbidity with attention-deficit hyperactivity disorder, 1029
diagnosis of, 1179–1180
drug treatment of, 1030
antipsychotics, 1213
mood stabilizers, 1180–1182
BIRD ventilator, for newborns, termination sensitivity mode of, 482
Bites, animal, dogs, 845, 846
of hand, 1521–1522
Bladder complications of cancer treatment, 1647
Bleeding. See *Hemorrhage.*
Bleomycin, complications of, 1644
Body fluids, composition of, 720–721
Body language, of adolescents with serious or sensitive issues, 193
Bone complications, from cancer treatment, 1644–1645
Bone scans, in hand disorders, 1512
Boutonniere deformity, 1519–1520
Bowen's disease, 1443
Brachiocephalic systolic cardiac murmur, 116
Brachycephaly, 1548
clinical presentation, 1548–1549
diagnostic studies, 1549, 1551
treatment, 1551–1552
Bradycardias, 912
Brain injuries, 854–855. See also *Head injuries.*
Branchial cleft anomalies, diagnosis, 893, 894
embryology, 892–893
treatment, 893, 895
Breast cancer, oral contraceptives and, 1675, 1677
Breast development, 1674
Breast disease, postnatal, 1662
Breast surgery in adolescents, 1496
female breast and, 1496–1498
female macromastia, 1498–1499
gigantomastia, 1499
gynecomastia, 1500–1502

Breast surgery in adolescents *(Continued)*
male breast and, 1500
reductions, 1500
Breslow level, 1440
Bromocriptine, 1167
Bronchiolitis obliterans, 1644
Bronchogenic cysts, 870–871
Bronchopulmonary dysplasia, **573–586**
changes in neonatal respiratory care with, 581–582
etiology, 573–574
long-term lung function in, 582
in neonatal intensive care unit graduate, 86–89
history and physical examination, 87–88
neurologic examination, 88
respiratory examination, 88
pathogenesis, 578–579
surfactant administration for, outcomes following, 579–581
Bronchopulmonary sequestration, fetal surgery for, 601
Bruises and bites, evaluation of, for physical abuse, 207–208
Bruxism, orthodontics and, 1593–1594
Bullies, 33–34, 46
Bupropion, 1077, 1162
Buried knot suture, 842
Burning, child maltreatment by, 417
Burns, evaluation of, for physical abuse, 208–209
minor, 845–847
Burn scars, plastic surgery for, 1503
Buspirone, 1163–1164
in anxiety disorders, 1199
in depression, 1166
drug interactions with, 1241, 1250, 1254
Butyrophenones, drug interactions with, 1250

Café-au-lait spots, 1447–1448
CAGE questionnaire, for adolescents with serious or sensitive issues, 197
Calan's triad, 1484
Calcaneal apophysitis, 238
Calcium, in neonatal cardiopulmonary resuscitation, 595
Calcium carbonate, of oyster shell origin, in osteoporosis, 1675
California Z codes, for neonatology, 625
Cancer, **1637–1658**
evaluation of long-term survivors, 1639
general considerations, 1637–1638
head and neck neoplasms, 903
in lymphadenopathy, 882–883
ovarian, 1661–1662
treatment complications, cardiovascular, 1642–1643
genitourinary, 1646–1647
gonadal function and reproduction, 1647–1648
hearing, 1641
liver and intestines, 1646
musculoskeletal, 1644–1645
in pregnancy, 1648–1649
pulmonary, 1644
second malignancies, 1649
surgical, 1638, 1640
teeth and salivary glands, 1641–1642
thyroid, 1645
vision, 1640–1641
Cannulation, arterial, 1390–1391
Cantharidin, 1442
Cantrell, pentalogy of, 866
Capillary malformation, 1449–1451, 1470–1471
Carbamazepine, 1177–1178
in bipolar disorders, 1181
in conduct disorder, 1182
in depression, 1166
drug interactions with, 1241, 1244, 1245, 1248, 1251, 1253, 1255
Cardiac failure, from cancer treatment, 1643
Cardiac murmur, **105–120**
aortic systolic, 116–117
brachiocephalic systolic, 116
classification, 108–111
evaluation of, 111–113
innocent, 113–114
innocent, definition of, 106
normal continuous, 117–119
of peripheral pulmonary arterial stenosis, 115–116
pulmonary flow, 114–115
supraclavicular systolic, 116
vibratory Still's, 114
Cardiac surgery patients, former, care of, **907–941**
cardiac problems, arrhythmias, 910–911
supraventricular, 911–912
ventricular, 912–913
endocarditis, 918–920
physical examination, 909–910
residual or recurrent lesions, 913–915
sudden cardiac death, 913
valve and prosthesis problems, conduits and prosthetic patch materials, 917–918
prosthetic valves, 915–917
valvotomy, 915
ventricular dysfunction, 918
categories of congenital heart defects and their repair, 907–908
general postoperative problems, 908–909

noncardiac problems, exercise and participation in sports, 922–923
general health management, 923–925
growth and development, 921–922
specific defects, 925
complex heart defects, aortic valve stenosis and bicuspid aortic valve, 930–931
atrioventricular septal defects, 933–934
single ventricle and Fontan operation, 936–938
tetralogy of Fallot, 931–933
transposition of great arteries, 934–936
simple heart defects, atrial septal defects, 926–927
coarctation of aorta, 929–930
patent ductus arteriosus, 925–926
pulmonic valve stenosis, 928–929
ventricular septal defects, 927–928
team approach, 908–909
Cardiac transplantation. See *Heart transplantation.*
Cardiopulmonary bypass, inhaled nitric oxide therapy after, 538
Cardiopulmonary resuscitation, neonatal, **587–598**
in delivery room, 591
development of, natural history of, 588–590
initial evaluation and stabilization, 590–592
for meconium aspiration, 592–593
medications with, 593–596
atropine, 596
calcium, 595
epinephrine, 593–594
naloxone, 594–595
sodium bicarbonate, 595
volume expansion, 595
ventilation, 592
Cardiovascular complications of cancer treatment, 1642–1643
Cardiovascular effects of tricyclic antidepressants, 1195–1196
Caries, dental, 1585–1588
Carmustine, complications of, 1644, 1646
Carpenter syndrome, 1550
Cataracts, 1005–1006
Catheters, central venous, 1329, 1380–1382
complications, acute, 1384–1385
long-term, 1388, 1390
intraosseous, 1376–1377
percutaneous peripheral, 1373–1375
peripheral intravenous central, 1379–1380
peripheral venous cutdown, 1375–1376
Cat scratch disease, 881, 902–903
Caudal agenesis, 1572, 1574
Caudal blocks, 1534
Cellulitis, facial, from dental caries, 1587
of hand, 1522
Central nervous system, and causes of weakness/clumsiness, 146
and motor control, 145
Central venous access, central venous catheters for, 1380–1382
implantable access ports, 1383
other surgical access sites, 1383–1384
peripheral intravenous central catheters for, 1379–1380
umbilical vascular access, 1383
Central venous catheters, 1329, 1380–1382
Cephalometric radiographs, 1592
Cerebral palsy, 952–954
evaluation, theoretical framework for, 122
in neonatal intensive care unit graduate, 91, 93–94
in very low birthweight infants, 676–678
Cerebrospinal fluid, in hydrocephalus, 1540, 1542
Cervical esophagostomy, 1329–1330
Cervical lymphadenitis, 900–901
Cervical lymphadenopathy, 899–900
bacterial causes of, 879–881
Kawasaki's disease, 883
malignancy in, 882–883
miscellaneous causes of, 883
viral causes of, 877–879
Cervical spine, sports injuries to, 224
Chemosurgery, 1441–1443
Chemotherapy. See *Cancer, treatment complications.*
Chest lesions, **861–874**
chest wall, anomalies/deformities, 866
masses, 866
pectus carinatum, 865–866
pectus excavatum, 863–865
scoliosis, 861–863
parenchymal lung disease, congenital cystic masses, 870–871
esophageal foreign bodies, 869–870
foreign body aspiration, 869
mediastinal masses, 872
pulmonary hemorrhage, 872
tumors, 873
pleural disease, empyema, 868–869
pneumothorax, 867–868
Chest wounds, suturing, 838
Chiari malformation, 1563–1565
Child abuse, 416–418
adolescent suicide, 421
cultural factors in, 416
evaluation for, **203–217**
historical perspective, 392
methods, burning, 417

Child abuse *(Continued)*
cutting, 417
female genital mutilation, 419–420
homicide and assault, 420
infanticide, 417–418
land mines, 423–424
sexual abuse, 418–419
wars, displacement, and ethnic cleansing, 421–423
minor injuries from, 844
physician relationship after investigation, 398–399
prevalence and risk factors, 391–392
prevention, 399
psychosocial aspects, **391–402**
recognition, 392–395
interview, 393–395
social history, 393
reporting, 395–398
documentation, 397–398
multidisciplinary environment, 396–397
treatment, 398
Child & Adolescent Symptom Inventories, 1061
Child Behavior Checklist, 1044
Child find, in early intervention system, 706–707
Child rearing, cultural differences in, 416
Children, daily problems with, 26
Children's Coma Scale, 834
Children's Depression Inventory, 1044
Chlamydial infections, 1684
Chloroacetic acid, 1442
Chlorpromazine, 1208–1209, 1210
Cholangitis, in hepatic portoenterostomy, 1343
Cholecystitis, acalculous, 760–761
presenting characteristics, 730
Cholelithiasis, 730, 759–760
Cholesteatomas, tympanostomy tubes and, 981
Chondromalacia patellae, 1618
Chorioamnionitis, with meconium-stained amniotic fluid, neonatal outcome with, 516–517
Chorionic gonadotropin, human (HCG), in cryptorchidism, 817, 819
Cigarette consumption, as consequence of media violence, 327
Cimetidine, drug interactions with, 1245, 1248, 1254
Ciprofloxacin, drug interactions with, 1249
Circumcision, recommendations, 802–803
routine neonatal (and controversies), 801–802
techniques, 803–805
Cisapride, drug interactions with, 1241, 1255
Cisplatin, complications of, 1641, 1646
Citalopram, 1140, 1167, 1193
Clarity, in neonatal risk assessment, 660
Clavicle fractures, 1608–1610
Cleft lip and palate, 1479
alveolar reconstruction in, 1494–1495
classification, 1484
dentistry and, 1583
diagnosis, 1486
embryology, 1480
etiology, 1482–1484
genetic counseling for, 1484
incidence and epidemiology, 1481–1482
middle ear disease in, 1495
nomenclature, 1480–1481
residual nasal deformities, 1495
secondary deformities, 1495–1496
speech development after cleft palate repair, 1493–1494
submucous cleft palate, 1494
treatment, 1484
cleft lip repair, bilateral, 1489–1490
postoperative management, 1490–1491
unilateral, 1488
cleft palate repair, 1491
postoperative management, 1491, 1493
presurgical orthopedics, 1487
timing of procedures, 1487
types of deformity, 1483
Clinical trial study design, future of, 1274
Cloaca, 1358–1362
exstrophy, 1362–1364
preoperative and postoperative anatomy, 1362
Clomipramine, 1125. See also *Antidepressants, tricyclic; Selective serotonin reuptake inhibitors.*
in anxiety disorders, 1190
in obsessive-compulsive disorder, 1139
Clonazepam, in anxiety disorders, 1197
extrapyramidal side effects treated with, 1220
Clonidine, 1526. See also *Alpha–2 adrenergic agonists.*
adverse effects of, 1115
in attention-deficit hyperactivity disorder, 1065, 1077
in case vignettes, 1117, 1118
clinical applications and efficacy, 1100, 1109–1111, 1112
dosing, 1115
drug interactions with, 1243, 1245, 1251
medical work-up for, 1116
methylphenidate with, 1116–1117
properties of, 1114
studies of, 1104–1107
Clotrimazole, 1267

Clozapine, 1167, 1206, 1207
in autistic disorder, 1215
drug interactions with, 1241, 1250, 1254–1255
in schizophrenia, 1212
seizures and, 1221–1222
studies of, 1210
in Tourette's syndrome, 1216
use of, 1222–1223
Clumsiness, approach to, **143–166.** See also *Weakness/clumsiness.*
Coarctation of aorta, 929–930
Codeine, drug interactions with, 1239, 1241
Cognition, after organ transplantation, 1409
Cognitive-behavioral therapy, for post-traumatic stress disorder, 348
Colitis, ulcerative, 1300, 1301
Colloid fluid, 1530
Colorectal carcinoma, 1368
Colostomy, 1333. See also *Intestinal ostomies.*
Coma, definition of, 138
Coma scales, 834–835
Community, in suicide, 373
Community-acquired viruses, in organ transplantation, 1406
Community gatekeeper training programs, for suicide prevention/intervention, 374
Community-level resilience, for violence, 297–298, 301
Community-level risk, for violence, 300
Compartment syndrome, 1520–1521
Complement receptor 3 deficiency, 796
Computed tomography, in spleen injury, 856
Condoms, 1685
Conduct disorder, 1041–1042. See also *Disruptive behavior disorders.*
antipsychotics in, 1214
attention-deficit hyperactivity disorder with, 1057–1058
mood stabilizers in, 1182
Confidentiality, for adolescents with serious or sensitive issues, 190–192
Confusion, definition of, 138
Congenital anomalies, presenting as primary amenorrhea, 1674
Congenital cystic adenomatoid malformations, 601, 870–871
Congenital diaphragmatic hernia, fetal surgery for, advances in, 600–601
in intensive care nursery graduate, 1347–1349
neonatal surgery for, advances in, 613–614
surfactant for, 561–562
Congenital head and neck lesions, 890–899
Congenital heart disease. See also *Cardiac surgery patients.*
categories of, and their repair, 907–908
complex defects, 930–938
inhaled nitric oxide for, 537–539
simple defects, 925–930
Congenital nevomelanocytic nevus, surgical management, 1447–1449
Conners' Rating Scales, 1061
Consciousness, levels of, 138
altered, in neurologically impaired child, 139
Consent for psychotropic medications, 1027–1028
Constipation, after anorectal malformation repair, 1341
Hirschsprung's disease in, 1287–1294
Contact dermatitis, intestinal ostomies and, 1432
Content validity, in neonatal risk assessment, 657
Continuous cardiac murmur, classification of, 110–111
normal, 117–119
Contraceptives, oral. See *Oral contraceptives.*
Conversion disorder, weakness/clumsiness in, identification of, 163
Copeland Symptom Checklist for ADD, 1061
Copper deficiency, 254–255
Coronary artery disease, as cancer treatment complication, 1643
Corporal punishment, **403–414**
consensus statements on, 409–411
conventional wisdom on, 404
implications of, 411–412
opinions about, 403
scientific evidence on, 404–409
arguments against, 406–407
arguments for, 405–406
common practice, 404–405
limitations of current research, 408–409
Corticosteroids, for hemangiomas, 1467–1468
for lichen sclerosis, 1672–1673
for scars, 1502
in sinusitis, 983–984
CPT coding, process of, for neonatology, 623
Cranioectodermal dysplasia, 1550
Craniofrontonasal dysplasia, 1550
Craniospinal dysraphism, caudal agenesis, 1572, 1574
classification, 1562
myelomeningocele, 1562–1565
occult spinal dysraphism, 1565
dermal sinus tracts, 1567–1569

Craniospinal dysraphism *(Continued)*
spinal lipomas, 1565–1567
split cord malformations, 1569–1571
thickened filum terminale, 1571
terminal myelocystocele, 1571–1572, 1573
Craniosynostosis and abnormally shaped head, 1545, 1548
asymmetric head (plagiocephaly), 1554–1561
genetic syndromes in, 1550
long head (dolichocephaly), 1552–1554
microcephaly, 1561–1562
short head (brachycephaly), 1548–1549, 1551–1552
triangular shaped head (trigonocephaly), 1554
Criminality, violent, as consequence of violence, 336–338
Crisis, family, 30, 45
Crisis centers/hotlines, for suicide prevention/intervention, 374
Criterion validity, in neonatal risk assessment, 657
Crohn's disease, 1300, 1301
Cromolyn, 1267
Crouzon's disease, 1549, 1550
Cryosurgery, 1441
Cryptorchidism, 813, 1347
complications, 817–818
diagnostic techniques, 817
ectopic testes, 815
iatrogenic, 1346
physical examination, 815–817
retractile testis, 814
testicular descent and, 814
treatment, 818–819
Crystalloid solutions, 1530
Cushing's ulcer, 1299
Cutaneous trauma, evaluation of, for physical abuse, 207–209
Cutis marmorata, 1471
Cutis marmorata telangiectatica congenita, 1471–1472
Cutting, child maltreatment by, 417
Cyanocobalamin deficiency, 253
Cyanosis, chronic, ventricular dysfunction from, 918
Cyclophosphamide, complications of, 1644, 1646, 1647, 1648
Cyclosporine, drug interactions with, 1255
in organ transplantation, 1396, 1397, 1399–1400
Cyclothymia, 1179–1180
Cyproheptadine, drug interactions with, 1241
Cystic adenomatoid malformation, congenital, 601, 870–871
Cystic hygromas, 890–891
Cystic masses of lung, congenital, 870–871
Cystitis, hemorrhagic, 1647
Cysts, dermoid and epidermoid, 897–898
hepatic, 1312
ovarian, neonatal and pediatric, 1659–1661
preauricular, 895–896
thyroglossal duct, 896–897
urachal and vitelline, 795
Cytochrome P-450, 1146–1148, 1149, 1234–1236, 1240
Cytomegalovirus, in organ transplantation, 1403–1405, 1407

Dacron grafts, in cardiac surgery, 917–918
Danazol, in endometriosis, 1682
Dance's sign, 748
Dating violence, **381–390**
contrasts with marital violence, 383
dynamics, 383–384
gender differences in, 383
health care response to, 385–387
helping victims of, 387
identification and assessment of, 386
intervention, 387–388
perpetrator gender, 382
prevalence, 382–383
prevention, 388, 446
risk markers of, 384–385
stability of, 383
victim gender, 382
Daunorubicin, complications of, 1643
Death of baby, in Infant Special Care Unit, **691–699**
Deep palmar space abscesses, 1523
Delirium, definition of, 138
Dental care, 1579–1580
in transplant recipients, 1411–1412
Dental problems, **1579–1600**
caries, 1585–1588
initial visit for, 1580–1583
orthodontics for, 1590–1594
preventive dentistry for, 1589–1590
trauma, 1594
of permanent dentition, 1597–1598
of primary dentition, 1594–1597
Dentinogenesis imperfecta, 1584
Dentistry, pediatric, 1579
Denver Developmental Screening Test, in severe neurologic impairment, 124
de Pezzer gastrostomy tube, 1330, 1426
Depression, 1040–1041
in adolescents, violence prevention strategies with, 444
Children's Depression Inventory, 1044
drug treatment of, 1030
antipsychotics, 1213
selective serotonin reuptake inhibitors, 1139–1140, 1158

tricyclic antidepressants, 1127–1128
Dermal sinus tracts, 1567–1569
Dermatitis, with intestinal ostomies, 1432–1433
Dermatologic history, in children, 49–50
Dermatologic surgery, **1437–1453**
basic office surgery, anesthesia, 1438–1439
chemosurgery, 1441–1443
cryosurgery, 1441
skin biopsy, 1439–1441
for specific conditions, aplasia cutis congenita, 1446–1447
congenital nevomelanocytic nevus, 1447–1449
nevus sebaceus, 1443, 1446
port-wine stains (and laser use), 1449–1451
Dermoid cysts, 897–898
Desipramine, 1125. See also *Antidepressants, tricyclic.*
in attention-deficit hyperactivity disorder, 1126
cardiovascular effects of, 1196
Development. See also *Growth.*
disorders associated with puberty, 1673–1680
in former cardiac surgery patient, 921–922
gastrostomy tubes and, 1424
motor milestones, 151
normal, relationship to violence, 283–284
after organ transplantation, 1408–1411
pervasive disorders, alpha–2 adrenergic agonists in, 1112
antipsychotics in, 1214–1215
physical examination and, **1–23**
psychopathology, 284–285
in adolescent suicide, 367–368
strengths and limitations of, 285
use in addressing violence, 284
psychopharmacology and, **1021–1035**
in severe neurologic impairment, progress of, 124–127
in sexual abuse, 211–212
tooth, 1581, 1583–1585
in very low birthweight infants, outcome of, **673–690**
Developmental delay, in congenital diaphragmatic hernia, 1349
Developmental hip dysplasia, 948–952
Dexfenfluramine, drug interactions with, 1241
Dextroamphetamine, in attention-deficit hyperactivity disorder, 1029, 1064, 1070–1073, 1086–1087, 1090, 1095
and levoamphetamine (Adderall), 1065, 1070, 1087–1088, 1090
Dextromethorphan, drug interactions with, 1241, 1256
Diagnostic category, in neonatal risk assessment, 655
Diagnostic evaluations, in early intervention system, 707
Diaphragmatic hernia, congenital. See *Congenital diaphragmatic hernia.*
Diastasis recti abdominis, 786
Diastolic cardiac murmur, classification of, 109–110
Diazepam, 1529
drug interactions with, 1242
Diet. See also *Nutrition.*
dental caries and, 1586
intestinal ostomies and, 1434
DiGeorge syndrome, 924
Digital amputations, traumatic, 1521
Digital blocks, 1513–1514
Digoxin, 1526
Diltiazem, drug interactions with, 1245
Diphenhydramine, drug interactions with, 1245, 1251
extrapyramidal side effects treated with, 1220
Diplegia, clinical approach to, 158–159
Discipline, **403–414.** See also *Corporal punishment.*
cultural differences in, 416
violence prevention and, 441
Disease management, model of, 651–653
in neonatology, **651–672**
Disruptive behavior disorders. See also *Conduct disorder.*
alpha–2 adrenergic agonists in, 1109–1112
antipsychotics in, 1214
Distribution of drug, 1022
Diuretics, thiazide, drug interactions with, 1253
Divalproex, in conduct disorder, 1182
Divorce, 29, 45
Documentation, in neonatal risk assessment, 661
Dog bites, 845, 846
Dolichocephaly, 1552–1554
Domestic violence, prevention of, 440
Dopamine receptor agonists and antagonists, 1167
Dopaminergic antidepressants, 1167
Dopamine uptake and release, drugs affecting, 1167
Double-barrel ostomy, 1431
Doxorubicin, complications of, 1643
Drash's syndrome, 1308
Droperidol, 1209
Drowsiness, definition of, 138
Drug abuse, 1041
in adolescents, 310–312
suicide and, 369–370
violence prevention strategies with, 444

Drug abuse *(Continued)*
in children witnessing violence, 358
psychiatric disorders and, 1023
Drug-drug interactions, **1233–1264**
metabolic-based, 1234–1236
pharmacokinetic basis of, 1234
for psychoactive medications, 1236
benzodiazepines, 1199, 1244, 1248–1249
buspirone, clozapine, nefazadone, and MAOIs, 1250, 1254–1256
lithium, 1250, 1253
mood stabilizers, 1175, 1176, 1178
neuroleptics, 1250–1252
selective serotonin reuptake inhibitors, 1145–1148, 1194, 1237, 1239–1243
stimulants, 1236–1237, 1238
tricylic antidepressants, 1196–1197, 1240, 1244–1247
Drugs. See also *Psychopharmacology.*
in adolescents with serious or sensitive issues, 196–198
development of, future of, 1275–1276
Dubowitz neurologic examination, 92
Duhamel's side-to-side rectal colonic anastomosis, 1288, 1292, 1293
Dumping syndrome, 1422
Duodenal atresia, neonatal surgery for, 607–608
Duplications, alimentary tract, 1300
Dynamic Orthotic Cranioplasty, 1561
Dysfunctional child, diagnosis of, historical clues to, **25–48**
history taking, 27–38
assessment of severity, 38–39
screening questionnaires, 39–41
interviewing, 26–27
psychosocial questions for, 45–48
risk and protective factors in, 40
Dysmorphology, physical examination for, in severe neurologic impairment, 130–134
Dyspraxia, clinical approach to, 148
Dysraphism. See *Craniospinal dysraphism.*

Earlobes, torn, plastic surgery for, 1503
Early systolic cardiac murmur, classification of, 108
Ear wounds, suturing, 838
ECMO. See *Extracorporeal membrane oxygenation.*
Ectopic anus, 1356–1358
Ectopic testes, 815
Edema, pulmonary, 1531–1532
scrotal, 824
Education, of adolescents with serious or sensitive issues, 195–196
for organ transplantation, 1413
Ejection cardiac murmur, classification of, 108
Elbow injuries, differential diagnosis, 221
in sports, 227–229
medial collateral ligament and apophyseal injuries, 1613, 1615
osteochondritis dissecans, 1612–1613
Panner's disease, 1613
Electrolytes. See also *Fluid therapy for surgical patient.*
anesthesia and, 1530
in body fluids, 725
renal, fluid physiology and, 721–722
Elimination of drug, 1022–1023
Emergency department, violence in, **449–457**
legal issues involving, 453–456
EMLA cream, in dermatologic surgery, 1438–1439
Emotional health, in childhood psychiatric disorders, 35, 46–47
after organ transplantation, 1409
Emphysema, congenital lobar, 870
Employment, of adolescents with serious or sensitive issues, 195–196
Empyema, 868–869
Endocarditis, in former cardiac surgery patient, bacterial, 918–920
prosthetic valve, 917
Endometriosis, 1680
alternative therapies and co-conditions, 1683
clinical response to treatment, 1683
diagnosis, 1680–1681
future fertility considerations in, 1683–1684
medical therapy, 1681–1682
natural history, 1681
surgical therapy, 1682–1683
Endorectal pull-through procedures, 1338–1339
Endoscopic sinus surgery, functional, 984–985
Endoscopic third ventriculostomy, 1542
End ostomy, 1431
Enemas, contrast, in intussusception, 748–751
Enteral nutrition, for intensive care nursery graduate, 1327–1328
Enterocolitis, Hirschsprung's, 1294, 1338
necrotizing, 1299
in intensive care nursery graduate, 1336–1337
neonatal surgery for, 609
Enuresis, tricylic antidepressants in, 1127
Epidermoid cysts, 897–898
Epididymitis, 823–824
Epidural anesthesia, 1529, 1534

Epigastric hernia, 787
Epinephrine, in dermatologic surgery, 1438
  drug interactions with, 1251
  in neonatal cardiopulmonary resuscitation, 593–594
Epispadias, 809
Epstein-Barr virus, lymphoproliferative disorders and, in organ transplantation, 1405, 1407
Equinovarus deformity, with peripheral nerve weakness, 160
Esodeviations, 997–1000
Esophageal atresia, neonatal surgery for, 606
  and tracheoesophageal fistula, 1335–1336
Esophageal foreign bodies, 869–870
Esophagitis, 1298
Esotropia, 995
  accommodative, 998–1000
  congenital, 997–998
Estrogen, hypoestrogenism, 1674–1675
  low, in childhood, pathology associated with, 1667–1673
  transdermal skin patch, 1668
Estrogen withdrawal bleeding, 1662
Ethanol, drug interactions with, 1256
Ethnic cleansing, child maltreatment in, 421–423
Eustachian tube dysfunction, tympanostomy with tube insertion for, 979
Eutectic mixture of local anesthetics (EMLA), in dermatologic surgery, 1438–1439
Exercise, in former cardiac surgery patient, 922–923
  intolerance, in pectus excavatum, 864
  in transplant recipients, 1413
Exodeviations, 1000–1002
Exotropia, 995–996
  congenital, 1000
  intermittent, 1000
  treatment, 1000–1002
Extensor tendons of hand, 1509
  lacerations of, 1516–1517
External jugular vein, as access site, 1374–1375
  location and anatomy, 1377
Extracorporeal membrane oxygenation, care of survivors of, 1349–1350
  studies of, 536
  surfactant use with, 560
  with ventilation, in acute respiratory failure in newborns, 492–493, 499–501
Extrapyramidal side effects of antipsychotics, 1217, 1219–1221
Extrauterine intrapartum treatment (EXIT), 603
Extremity wounds, suturing, 838
Face validity, in neonatal risk assessment, 657
Facial wounds, suturing, 838
Failure to thrive, causes of, 168
  in congenital diaphragmatic hernia, 1348
  definition of, 167
  evaluation of, **167–185**
    assessment and plan, 183
    family history, 174
    history-searching for risk factors, 170–177
      nutritional history, 176–177
      past medical history, 172–174
      postnatal history, 174
      present illness, 171–172
      social and developmental history, 174–176
    laboratory testing, 181–182
    ongoing, 182–184
    physical examination, 177–181
    stepwise clinical approach, 169–170
Fallot, tetralogy of, 931–933
Family, in psychiatric disorders, 28–31
    attention-deficit hyperactivity disorder, 1063, 1066–1067
    crisis, 30
    drug treatment and, 1025–1026
    household stability, 28–29
    marital conflict and divorce, 29
    parental mental health, 30–31
    psychosocial questions about, 45
  in suicide, 372–373
Family-level resilience, for violence, 296–297, 301
Family-level risk, for violence, 300
Family service plan, individualized, in early intervention system, 707
Family system perspectives, on post-traumatic stress disorder, 347–348
Fasting before surgery, 1526–1527
Fatty acids, essential, deficiencies of, 246–248
Fecal incontinence, after anorectal malformation repair, 1341, 1342
Feeding, disorders, in neonatal intensive care unit graduate, 84–86
  disrupted, in infants witnessing violence, 358
  history, in severe neurologic impairment, 128
  tubes. See *Gastrostomy.*
Felons, 1522
Female athletic triad, 1675
Femoral epiphysis, slipped capital, 945–948, 1615–1616, 1617
Femoral hernia, 785–786
Femoral region anatomy, 1376
Femoral torsion, 962–963, 966
Femoral vein, as access site, 1374

Fenfluramine, drug interactions with, 1241
Fertility, endometriosis and, 1683–1684
Fetal surgery, **599–604**
  for bronchopulmonary sequestration, 601
  for congenital cystic adenomatoid malformation, 601
  for congenital diaphragmatic hernia, 600–601
  for sacrococcygeal teratoma, 602
  for twin-to-twin transfusion, 602–603
  for urinary tract obstruction, 600
α-Fetoprotein, in liver tumors, 1316
Fever, in infant, **65–77**
  antipyretic effect on, 74–75
  clinical appearance, 67–69
  history taking for, 65–66
  older than 8 weeks of age, 71–75
  parental grading of illness severity, reliability of, 74
  physical findings, 66–67
  predictive value of observation scales, 75
  younger than 8 weeks of age, 69–71
Fibrosis, pulmonary, from cancer treatment, 1644
Fighting, adolescent, alcohol intake and, 308–309
  drug abuse and, 312
  prevention strategies for, 445
  sexual behavior and, 314
Fight-or-flight response, 1101
Filum terminale, thickened, 1571, 1572
Financial future shock, in neonatology, **619–633**
Fingers, traumatic amputations of, 1521
First heart sound, 107
Fissures, anal, 1300, 1366
Fistulas, fistula-in-ano, 1365–1366
  mucous, 1431
  persistent gastrocutaneous, 1424
  umbilical and vesicoumbilical, 795
Flail chest, 866
Flashlamp-pulsed dye laser, 1450, 1471
Flesinoxan, 1166–1167
Flexor sheath blocks, 1513
Flexor sheath infections, 1522–1523
Flexor tendons of hand, 1508–1509
  lacerations of, 1516
Fluid collections, benign extra-axial, of infancy, 1544–1548
Fluid loss, in pyloric stenosis, 742
Fluid therapy for surgical patient, **719–727**
  anesthesia and, 1530
  clinical scenarios, appendicitis, 726
    oral rehydration solutions, 726–727
    pyloric stenosis, 725–726, 744
  paradigm for, 722
    deficit therapy, 722–723
    maintenance therapy, 723–724
    replacement therapy, 724–725
  renal physiology and, 720–722
Fluoride, in preventive dentistry, 1589
5-Fluorouracil, 1442–1443
Fluoxetine, 1267. See also *Selective serotonin reuptake inhibitors.*
  in anxiety disorders, 1140, 1192
  clozapine interacting with, 1254
  CYP–450 isozymes and, 1240
  dosing and cost of, 1150, 1151
  indications, 1137
  in major depressive disorder, 1030
  in mood depressive disorder, 1139–1140
  in obsessive-compulsive disorder, 1139
  suicidality and, 1143, 1194
Fluphenazine, 1206, 1210
Fluvoxamine. See also *Selective serotonin reuptake inhibitors.*
  in anxiety disorders, 1193
  clozapine interacting with, 1254
  CYP–450 isozymes and, 1240
  dosing and cost of, 1150
  drug interactions with, 1239–1240
  indications, 1137
  in obsessive-compulsive disorder, 1138–1139
Focal nodular hyperplasia, hepatic, 1312
Folate deficiency, 252–253
Foley catheter, 1426
Fontan operation, 936–938
Food and Drug Administration, regulatory changes in, 1266–1270
Foot, avulsion fractures, 237
  sports injuries, 235–238, 1629–1632
  wounds, suturing, 838
Forearm, sports injuries to, 227–229
Foreign bodies, 847–848
  aspiration of, 869
  esophageal, 869–870
  in hand, 1521
Forensic examination under anesthesia, in genital trauma, 1664–1665
Formulas, for intensive care nursery graduate, 1327–1328
Fractures, clavicle, 1608–1610
  foot, 237
  hand, 1519, 1520
  pelvis, 1616–1618
  proximal humerus, 1610–1612
  tooth, 1595, 1596, 1597–1598
French angles neurologic examination, 92
Friends, in childhood psychiatric disorders, 33, 46
Frustration among adolescents, violence prevention strategies and, 444
Functional endoscopic sinus surgery, 984–985
Furlow double opposing Z-plasty cleft palate repair, 1492

Future shock, financial, in neonatology, **619–633**

Gabapentin, 1178
Gait, idiopathic toe walking, 960–961
Galeazzi fracture, 1520
Galeazzi sign, 950
Gallbladder disease, 759–761
Ganciclovir, 1405
Ganglioneuroblastoma, 1302
Ganglioneuroma, 1302
Gardner's syndrome, 1296
Garment nevi, 1448
Gastritis, 1298–1299, 1683
Gastroduodenal ulceration, 1298–1299
Gastroesophageal reflux, 1298
  in congenital diaphragmatic hernia, 1348–1349
  after esophageal atresia repair, 1336
  in neonatal intensive care unit graduate, 85, 1333–1335
Gastrointestinal complications of cancer treatment, 1646
Gastrointestinal effects of selective serotonin reuptake inhibitors, 1141
Gastrointestinal hemorrhage, definitions, 1295
  diagnostic approaches, 1298–1299
  etiology, 1295
  initial evaluation, 1296
  lower, 1299–1301
  resuscitation in, 1296
  surgical disorders associated with, 1294–1301
  upper, 1296–1299
Gastroschisis, 1344
Gastrostomy, 1330–1332, 1419
  indications, 1419–1420
  long-term complications, 1421–1424
  postoperative care, 1430
  routine care of tubes and devices, 1424–1426
  specific tubes, Malecott, de Pezzer, and Foley catheters, 1426
    percutaneous endoscopic gastrostomy, 1429–1430
    skin-level devices, 1426–1429
  techniques, 1420–1421
General anesthesia, 1527–1529
Generalized anxiety disorder, 1188
Genetics, in adolescent suicide, 371
  heart defects in siblings of former cardiac surgery patient, 925
Genitalia, female, 214
Genital mutilation, female, 419–420
Genital trauma, 1662–1665
Genital warts, 1665–1667
Genitourinary complications of cancer treatment, 1646–1647
Germ cell tumors, 1661–1662
Gestational age/weight, in neonatal risk assessment, 654
Giant congenital/hairy nevi, 1448
Gigantomastia, 1499
Gingival hyperplasia, in transplant recipients, 1411–1412
Glasgow Coma Scale, 834
  in mild head injuries, 843–844
Glasgow Outcome Scale, 854
Glaucoma, infantile, 1003–1005
Gliding testicles, 816–817
Goldstein test, 785
Gonadal function, cancer treatment effects on, 1647–1648
Gonadotropin-releasing hormone, in varicocele, 826
Gonadotropin-releasing hormone agonists, in endometriosis, 1682
Government, psychopharmacology information and, 1266–1273
Graft rejection, in organ transplantation, 1400–1403
Graft-versus-host disease, 1412
Granulation tissue, in gastrostomy tubes, 1422–1423
Granuloma annulare, diagnosis of, 58–61
Granulomas, stomal, 989
  tympanostomy tubes and, 981
  umbilical, 793–794, 1345
Great arteries, transposition of, 934–936
Greater saphenous vein, as access site, 1374, 1375
Grieg cephalopolysyndactyly, 1550
Growth. See also *Development.*
  in former cardiac surgery patient, 921–922
  of neonatal intensive care unit graduate, 81–84
  after organ transplantation, 1408–1411
  psychostimulants and, 1067, 1094–1095
  tooth, 1583–1585
Guanfacine. See also *Alpha–2 adrenergic agonists.*
  adverse effects of, 1115–1116
  in case vignette, 1118
  clinical applications and efficacy of, 1111–1112
  dosing, 1115
  properties of, 1114–1115
  studies of, 1105–1107
Guns, injuries and deaths from, **427–438**
  costs of, 428
  homicide, 274–275
  magnitude of problem, 427
  prevalence of gun ownership, 428
  prevention of, 440

Guns *(Continued)*
design modifications for, 430–433
decreasing lethality, 432–433
preventing unauthorized use, 430–432
preventing unintended use, 432
regulation, legislation, and litigation, 433
future needs in, 434
reduction in number of guns, 429–430
strategies for, 428–433
injury control approaches, 428–429
product-oriented, 429–433
Gynecology, **1659–1688**
disorders associated with pubertal development, 1673–1680
estrogen withdrawal bleeding, 1662
genital warts, 1665–1667
ovarian pathology, 1659–1662
pathology associated with low-estrogen state, 1667–1673
pelvic inflammatory disease, 1684–1687
pelvic pain, 1680–1684
postnatal breast disease, 1662
sexual abuse versus innocent genital trauma, 1662–1665
Gynecomastia, 1500–1502

Haloperidol, 1206
in autistic disorder, 1214
in conduct disorders and aggression, 1214
drug interactions with, 1242
in schizophrenia, 1209, 1212
studies of, 1210
in tic disorder, 1216
Halothane, 1528
Hamartomas, hepatic, 1313
nevus sebaceus, 1443, 1446
Hand disorders, **1507–1524**
anatomy and function in, diagnostic studies, 1512
muscles and tendons, 1508–1509
neurologic examination, 1509–1510
vascular examination, 1510–1511
anesthesia in, digital blocks, 1513–1514
local anesthesia, 1512–1513
wrist blocks, 1514–1515
congenital abnormalities, 1523
evaluation, 1507–1508
infections, 1521–1523
neoplasms, 1523
sports injuries, 229–230
trauma, amputations, 1521
boutonniere and mallet deformities, 1519–1520
compartment syndrome, 1520–1521
dislocations and subluxations, 1520
foreign bodies, 1521
fractures, 1519
injection injuries, 1521
lacerations, 1516–1517
nailbed injuries, 1517–1518
nerve injuries, 1518
vascular injuries, 1518
wounds, suturing, 838
Harlem Hospital injury prevention program, for violence, 464–465
Head abnormalities, craniosynostosis and abnormally shaped head, 1545, 1548–1562
macrocrania, 1539–1545
Headache, ophthalmologic causes of, 995
spinal, 1529
Head and neck lesions, **889–905**
classification, 889
congenital, branchial cleft anomalies, 892–895
cystic hygromas, 890–891
dermoid and epidermoid cysts, 897–898
hemangiomas, 891–892
preauricular pits, sinuses, and cysts, 895–896
ranula, 898
thyroglossal duct cysts and sinuses, 896–897
torticollis, 899
evaluation, 889–890
inflammatory, acute suppurative cervical lymphadenitis, 900–901
cat scratch disease, 902–903
cervical lymphadenopathy, 899–900
mycobacterial lymphadenitis, 901–902
subacute or chronic cervical lymphadenitis, 901
neoplastic, 903
Head circumference, in failure to thrive, 178
Head growth, of neonatal intensive care unit graduate, 83, 91
Head injuries. See also *Brain injuries.*
evaluation of, for physical abuse, 209–210
mild, 843–844
Health management, for former cardiac surgery patient, 923–925
Hearing, assessment, of neonatal intensive care unit graduate, 96
cancer treatment complications of, 1641
Heart disease, congenital. See *Congenital heart disease.*
Heart monitor, tracheostomy and, 988–989
Heart murmur. See *Cardiac murmur.*
Heart sounds, 106–107
Heart surgery. See *Cardiac surgery patients.*

Heart transplantation, cyclosporine and tacrolimus levels after, 1399
exercise after, 1413
growth and development after, 1408, 1409
number of transplants, 1396
rejection of, 1401–1402
survival rates, 1396–1397
Heart valve and prosthesis problems, in former cardiac surgery patient, 915–918
Height, reduced, in failure to thrive, 178
Helplessness, learned, with exposure to violence, 344
Hemangioendothelioma, hepatic, 1313
kaposiform, 1462–1463
Hemangiomas, clinical course, 1457, 1462
differential diagnosis, 1463–1465
head and neck, 891–892
hepatic, 1313
history and physical examination, 1456–1457
illustrations, 1458–1463
incidence, 1456
kaposiform hemangioendothelioma, 1462–1463
malformative anomalies associated with, 1457
management, antiangiogenic pharmacologic therapy, 1467–1468
laser therapy, 1469–1470
observation, 1465
of obstructive complications, 1466–1467
surgery, 1468–1469
of ulceration and bleeding, 1466
periorbital, 1007–1008
radiologic evaluation, 1465
Hematochezia, 1295
Hematomas, subungual, 1517–1518
Hemiparesis, clinical approach to, 158
Hemodynamic overload, chronic, ventricular dysfunction from, 918
Hemorrhage, gastrointestinal. See *Gastrointestinal hemorrhage.*
from hemangiomas, 1466
intracranial, in neonatal intensive care unit graduate, 90
pulmonary, 562, 872
stomal, 1432
Hemorrhagic cystitis, 1647
Hemorrhagic telangiectasia, hereditary, 1472
Hemorrhoids, 1365
Henoch-Schönlein purpura, 824–825
Hepatic failure, pemoline and, 1093–1094
Hepatic portoenterostomy, 1343
Hepatic transplantation. See *Liver transplantation.*
Hepatic tumors. See *Liver tumors.*
Hepatoblastoma, 1314–1317
Hepatocellular carcinoma, 1314–1317
Hereditary hemorrhagic telangiectasia, 1472
Hernias, **773–789**
congenital diaphragmatic. See *Congenital diaphragmatic hernia.*
epigastric, 787
femoral, 785–786
inguinal. See *Inguinal hernia.*
lumbar, 787
spigelian, 787
umbilical, 796–797, 1345
Herpetic whitlow, 1523
Hidden testis. See *Cryptorchidism.*
High-risk health behavior, in adolescents, alcohol use, 307–309
drug abuse, 310–312
health-care provider role in, 314–315
HIV risk, 312–314
parenthood, 312–314
sexually transmitted disease, 312–314
tobacco use, 310
violence and, **307–317**
Hill-Sachs lesion, 1606, 1609
Hip, dysplasia, 138, 948–952
movement, orthopedic tests for, 138
slipped capital femoral epiphysis, 945–948
sports injuries, 231, 1615–1616
synovitis, transient, 959–960
Hirschsprung's disease, 1287–1288
clinical presentation and evaluation, 1289–1291
differential diagnosis, 1291–1292
epidemiology and anatomy, 1288–1289
in intensive care nursery graduate, 1338–1339
long-term complications, prognosis, and follow-up, 1293–1294
neonatal surgery for, 612–613
total colon, 1293
treatment, 1292–1293
ultrashort-segment, 1293
Hirschsprung's enterocolitis, 1294, 1338
Histiocytic necrotizing lymphadenitis, 883
History taking, in febrile infant, 65–66
HIV infection, risk in adolescents, 312–314
Hodgkin's disease, 882, 1649
Holosystolic cardiac murmur, classification of, 108
Home, of adolescents with serious or sensitive issues, 194–195
Home monitoring, of neonatal intensive care unit graduate, 89
Homicide, arrest rates for, by age, gender, and race, 277–279
child and adolescent, 187, 420

Homicide *(Continued)*
by guns, 274–275
international comparison of, 275–276
interstate rates of, 274–275
rates by age, gender and race, 271–274
trends in rates, 272
Horizontal mattress suture, 840
Hormones. See also *Gynecology.*
in cryptorchidism, 817, 819
Hospital gatekeepers, for suicide prevention/intervention, 375
Household stability, 28–29, 45
HPV infection, genital warts from, 1665, 1666, 1667
Huber needle, 1383
Human chorionic gonadotropin (HCG), in cryptorchidism, 817, 819
Human immunodeficiency virus, risk in adolescents, 312–314
Human papilloma virus, genital warts from, 1665, 1666, 1667
Humerus fractures, proximal, 1610–1612
Hydroceles, 786, 1346–1347
inguinal hernias versus, 780–781
Hydrocephalus, 1540
clinical presentation, 1540–1541
complications, 1542–1544
diagnostic studies, 1541
in neonatal intensive care unit graduate, 90
treatment, 1541–1542
Hydrops, 761
Hydrostatic reduction, in intussusception, 752
Hymen, imperforate, 1669–1670
Hyperactive-impulsive attention-deficit hyperactivity disorder, 1056
Hyperactivity. See *Attention-deficit hyperactivity disorder.*
Hypertension, pulmonary, persistent in newborn, inhaled nitric oxide for, 535–537
Hypertrophic pyloric stenosis. See *Pyloric stenosis.*
Hypertrophic scars, 1502
Hypoestrogenism, 1674–1675
Hypospadias, 807–809
Hypothyroidism, from cancer treatment, 1645
Hypoxic-ischemic encephalopathy, in neonatal intensive care unit graduate, 90

Ifosfamide, complications of, 1644, 1646, 1647
Ileocolic intussusception, 746
Ileostomy, 1332–1333. See also *Intestinal ostomies.*
Illinois Bone Marrow Aspiration Needle, 1377, 1378
Imaging, in abdominal diagnoses, appendicitis, 735–736
gastroesophageal reflux, 1334
Hirschsprung's disease, 1290–1291
inguinal hernia, 782
intussusception, 748–751
liver tumors, 1316
malrotation and midgut volvulus, 756–757
neuroblastoma, 1305
pyloric stenosis, 742
in craniospinal dysraphism, 1566, 1569, 1571
in craniosynostosis and abnormally shaped head, 1549, 1551, 1552, 1554, 1560
in cryptorchidism, 817
in hand disorders, 1512
of hemangiomas, 1465
in hydrocephalus, 1541
for orthodontics, 1591–1592
in orthopedics, adolescent idiopathic scoliosis, 955
back pain, 958
transient hip synovitis, 960
in sinusitis, 983
in spleen injury, 856
for tonsillectomy and adenoidectomy, 975
Imipramine, 1125. See also *Antidepressants, tricyclic.*
in anxiety disorders, 1190, 1194–1195
in attention-deficit hyperactivity disorder, 1126–1127
in mood depressive disorder, 1140
Immune system, modulation of, surfactant in, 557
Immunizations, in former cardiac surgery patient, 923
for transplant recipients, 1406–1407
Immunosuppressed patients, abdominal pain evaluation in, 762–765
Immunosuppression, in organ transplantation, 1396–1400
Impairment, in psychopharmacology, 1026–1027
Imperforate anus, 1353–1354
cloaca, 1358–1362
high, 1354–1355
low, 1355–1356
neonatal surgery for, 611–612
Imperforate hymen, 1669–1670
Implantable access ports, 1383, 1388
Inattentive attention-deficit hyperactivity disorder, 1057
Incontinence, fecal, after anorectal malformation repair, 1341, 1342

Infanticide, 417–418
Infantile glaucoma, 1003–1005
Infantile hemangioendothelioma, hepatic, 1313
Infants. See also *Neonates.*
  critically ill, outcome of, managed care and, **635–650**
    methodology of, 637–640
    results of, 640–649
  death of, **691–699**
    follow-up family care, 698–699
    after leaving hospital, 696
    lifelong mourning of, 698
    after months of illness, 696
    parental bereavement in, attitudes toward, 691–692
    range of experience of, 692–696
  febrile, history and physical assessments of, **65–77.** See also under *Fever.*
  low birth weight. See *Low birth weight infants.*
  physical examination of, 6–10
  premature. See *Premature infants.*
  states of consciousness of, 703
  very low birthweight. See *Very low birthweight infants.*
Infant Special Care Unit, death of baby in, **691–699**
Infections, catheter, 1388, 1390
  chlamydial, 1684
  in former cardiac surgery patient, 924
  hand, 1521–1523
  in lymphadenopathy, 877–881
  in organ transplantation, 1403–1407
  shunt, 1543–1544
  upper respiratory tract, 982, 1535
Infectious dermatitis, with intestinal ostomies, 1433
Infertility, in cryptorchidism, 818
Inflammation, pelvic, 1684–1687
Inflammatory bowel disease, 1300–1301
Inflammatory head and neck lesions, 899–903
Inguinal hernia, clinical features, examination, 777–780
    symptoms, 776–777
  differential diagnosis, 780–782
  embryology and anatomy, 773–776
  epidemiology, 776
  incarcerated, 758–759
    clinical characteristics, 730
    examination, 779
    management, 784
  in intensive care nursery graduate, 1345–1346
  neonatal surgery for, 614–615
  radiologic investigations, 782
  treatment, 782–784
    opposite groin management, 784–785
    reduction, 779, 780
Inguinal lymphadenopathy, 885
Inhalational anesthetics, 1528
Injection injuries of hand, 1521
Injuries. See also *Sports injuries; Trauma.*
  in adolescents, alcohol intake and, 308–309
    drug abuse and, 312
    violence prevention strategies for, 445–446
  in childhood psychiatric disorders, 36, 47
Injury Severity Score, 833, 836
Insulin, surgery and, 1526
Intensive care. See *Neonatal intensive care unit graduate.*
Interactions of drugs. See *Drug-drug interactions.*
Interarch relationships, 1591
Interferon-α, for hemangiomas, 1467
Internal jugular vein, accessing, 1381
  localizing, 1384–1385
  location and anatomy, 1380
Interviews, for child abuse, 393–395
  in psychiatric disorders, 26–27, 1042–1043
  techniques of, with adolescents with serious or sensitive issues, 193
Intestinal aganglionosis, congenital. See *Hirschsprung's disease.*
Intestinal complications of cancer treatment, 1646
Intestinal obstruction, in neurologically impaired child, 765–766
Intestinal ostomies, 1430
  activities and, 1434
  colostomy, 1333
  diet and, 1434
  ileostomy, 1332–1333
  indications, 1431–1432
  management, 1433–1434
  stomal complications, 1432–1433
  surgery, 1431
Intestinal rotation. See *Malrotation and midgut volvulus.*
Intestinal stricture, in necrotozing enterocolitis, 1337
Intra-arch relationships, 1590
Intracranial hemorrhage, in neonatal intensive care unit graduate, 90
Intracranial pressure, increased, in neurologically impaired child, 139
Intraosseous catheters, 1376–1377
Intrapartum treatment, extrauterine (EXIT), 603
Intravenous access, **1373–1393**
  arterial cannulation, 1390–1391
  central venous access, 1379–1384
  complications, acute, 1384–1385, 1388

Intravenous access *(Continued)*
long-term, 1388, 1390
indications, advantages, and disadvantages, 1374
peripheral venous access, 1373–1378
Intrinsic plus position, 1517
Intubation, 1531
Intussusception, 746–747
clinical presentation and evaluation, characteristics, 730
diagnostic studies, 748–751
history, 747–748
physical examination, 748
differential diagnosis, 751
epidemiology, 747
etiology and pathology, 747
outcome, 752
treatment, 751–752
Iontophoresis, in dermatologic surgery, 1439
Ipsapirone, 1166–1167
Iron deficiency, 255
Irritant dermatitis, with intestinal ostomies, 1432
Isoflurane, 1528

Jackson-Weiss syndrome, 1549, 1550
Jaundice, from biliary atresia, 1342–1343
Jeune syndrome, 866
Jones fracture, of foot, 237
Jugular vein, external, as access site, 1374–1375
location and anatomy, 1377
internal, accessing, 1381
localizing, 1384–1385
location and anatomy, 1380
Juvenile polyps, 1300

Kanavel, four signs of, 1522
Kaposiform hemangioendothelioma, 1462–1463
Kasabach-Merritt phenomenon, 1462–1463
Kawasaki's disease, 883
Keloids, 1502
Kernahan classification scheme, 1484
Ketorolac, 1529
Kidney injuries, 857
Kidney transplantation, cyclosporine and tacrolimus levels after, 1399
exercise after, 1413
growth and development after, 1408–1409
number of transplants, 1396
rejection of, 1401–1402
survival rates, 1396–1397
Kikuchi's lymphadenitis, 883
Klippel-Trenaunay syndrome, 1450, 1471, 1475
Knee, disease, 235
sports injuries, 231–235
anterior pain, 1618–1620
differential diagnosis, 233
ligament injuries, 1624–1628
meniscal injuries, 1622–1623
Osgood-Schlatter disease, 1621–1622
osteochondritis dissecans, 1628–1629
patellar malalignment and instability, 1620–1621
physical examination for, 232–234
Sinding-Larsen-Johansson disease, 1622
KOH preparation, in skin evaluation, 55
Kwashiorkor, definition of, 245

Labial adhesions, 1667–1669
Laboratory tests, in appendicitis, 735
Lacerations, hand, 1516–1517
Lachman's test, 233, 1625, 1626
Ladd's bands, 754
Lamotrigine, 1178–1179
Land mines, child maltreatment by, 423–424
Laparotomy, indications in immunosuppressed child, 765
Laryngospasm, 1531
Lasers, for hemangiomas, 1469–1470
for tattoo removal, 1503
for vascular malformations, 1450, 1471
Late systolic cardiac murmur, classification of, 109
Lenses, overcorrecting minus, 1001
Leptomeningeal melanocytosis, 1448
Leukemia, in lymphadenopathy, 882
Leukomalacia, periventricular, 91
Levoamphetamine and dextroamphetamine (Adderall), 1065, 1070, 1087–1088, 1090
Levodopa, drug interactions with, 1249
Lichen sclerosis, 1670–1671
differential diagnosis, 1671
treatment, 1672–1673
Lidocaine, in dermatologic surgery, 1438
Ligament injuries, of knee, 1624–1628
Lipomas, spinal, 1565–1567
Lipomyelomeningocele, 1565–1567
Liposuction, for gynecomastia, 1501
Lip wounds, suturing, 838
Liquid ventilation, in acute respiratory failure in newborns, 497–499
surfactant and, 565
Lithium, 1173–1175
in bipolar disorders, 1180, 1181

in conduct disorder, 1182
in depression, 1166
drug interactions with, 1242, 1250, 1252, 1253
in mental retardation with aggressive behavior, 1182–1183
Livedo reticularis, 1471
Liver complications of cancer treatment, 1646
Liver failure, pemoline and, 1093–1094
Liver transplantation, cyclosporine and tacrolimus levels after, 1399
exercise after, 1413
growth and development after, 1408, 1409
number of transplants, 1396
rejection of, 1401
survival rates, 1396–1397
Liver tumors, clinical presentation and evaluation, 1312–1313, 1315–1316
differential diagnosis, 1316–1317
epidemiology and genetics, 1312–1313, 1314–1315
etiology and pathology, 1314
historical perspective, 1314
prognosis, complications, and outcome, 1312–1313, 1317
staging, 1316
treatment, 1312–1313, 1317
Local anesthetics, for dermatologic surgery, 1438–1439
in hand disorders, 1512–1513
in mild injuries, 836–837
in postoperative pain management, 1533, 1534
Locked running suture, 839
Locus coeruleus, 1101–1102
Lomustine, complications of, 1646
Loop ostomy, 1431
Lorazepam, in anxiety disorders, 1197
Louis-Bar syndrome, 1472
Low birth weight infants, in-hospital death of, odds of, 641, 644–645, 647
management of, history and physical examination in, 79–104. See also *Neonatal intensive care unit graduate.*
Lower extremity, sports injuries to, ankle and foot, 235–238, 1629–1632
hip and pelvis, 231, 1615–1618
knee, 231–235, 1618–1629
Lower gastrointestinal bleeding, 1298, 1299–1301
Loxapine, 1206
in schizophrenia, 1209
studies of, 1211
Lumbar hernia, 787
Lumbar spine, sports injuries to, 224
Lung disease, chronic, in neonatal intensive care unit graduate, 86–89
in premature infants, causes of, 573–574
congenital cystic masses, 870–871
esophageal foreign bodies, 869–870
foreign body aspiration, 869
mediastinal masses, 872
pulmonary hemorrhage, 872
tumors, 873
Lung resections, 1349
Lymphadenitis, cervical, 900–901
histiocytic necrotizing, 883
mycobacterial, 901–902
Lymphadenopathy, **875–888**
abdominal, 884–885
anatomy and, 875–876
axillary and inguinal, 885
cervical, bacterial causes of, 879–881
Kawasaki's disease, 883
malignancy in, 882–883
miscellaneous causes of, 883
viral causes of, 877–879
etiology, 877–878
evaluation, 876–877
mediastinal, 883–884
Lymphatic malformation, 1472–1473
Lymph nodes, anatomy of, 875–876
Lymphoid polyps, 1300, 1368
Lymphomas, in lymphadenopathy, 882
Lymphoproliferative disorders, Epstein-Barr virus and, in organ transplantation, 1405, 1407

Macrocrania, benign extra-axial fluid collections of infancy, 1544–1545
etiology, 1539
hydrocephalus, 1540–1544
Macrolides, drug interactions with, 1249, 1254, 1255
Macromastia, 1498–1499
Macro-orchidism, 820–821
Macular stains, hemangiomas versus, 1463–1464
Major depressive disorder. See *Depression.*
Malabsorption, in necrotizing enterocolitis, 1337
Malecot catheter, 1426
Malecot gastrostomy tube, 1330
Malignancy. See *Cancer.*
Mallet deformity, 1519–1520
Malrotation and midgut volvulus, 752–753, 1337–1338
clinical presentation and evaluation, characteristics, 730
diagnostic studies, 756–757
history, 755
physical examination, 755
complications and outcome, 758

Malrotation and midgut volvulus *(Continued)*
embryology, 753
neonatal surgery for, 608–609
pathology, 753–754
treatment, 757–758
Mammary artery soufflé cardiac murmur, 117–118
Manometry, anorectal, in Hirschsprung's disease, 1290
Marasmus, definition of, 243, 245
Marital conflict, 29, 45
Mask induction, 1528
Mass media, adverse impact of, prevention of, recommendations for, 327
Masterson's windows, 1680
Maxillary hypoplasia, in cleft lip and palate, 1495
McCune-Albright syndrome, 1667
McMurray test, 234, 1623
Meatal stenosis, 807
Meckel's diverticulum, 794–795, 1299–1300
Meconium aspiration syndrome, **511–529**
brain injury with, 524
delivery room management, 517–518
demography, 511–512
inflammation with, 515
lung appearance in, 513–514
microscopic appearance, 522–523
neonatal cardiopulmonary resuscitation for, 592–593
new therapies, 521–524
pathophysiology, 512–515
saline lavage treatment, microscopic appearance of, 522
surfactant for, 554–556
issues in, 518–521
microscopic appearance with, 523
toxicity with, 515–516
Meconium-stained amniotic fluid. See *Amniotic fluid, meconium-stained.*
Medial collateral ligament injuries, of elbow, 1613, 1615
of knee, 1624, 1627
Median nerve block, 1515
Mediastinum, lymphadenopathy, 883–884
masses, 872
Media violence. See *Violence, media.*
Medications. See *Drugs; Psychopharmacology.*
Melanocytosis, leptomeningeal, 1448
Melanoma, nevi and, 1448–1449
skin biopsy in, 1440
Melena, 1295
Menarche, delayed onset of, 1674–1675
Meniscal injuries, 1622–1624
Mental retardation, with aggressive behavior, mood stabilizers in, 1182–1183
antipsychotics in, 1215–1216
in very low birthweight infants, 676
Meperidine, drug interactions with, 1256
Merchant view radiograph, of patellar alignment, 1620
Mesoridazine, 1206
Metabolism, drug, 1022
Metaiodobenzylguanidine scintigraphy, in neuroblastoma, 1305
Metaproterenol, 1267
Methotrexate, complications of, 1644
Methylphenidate, 1267
in attention-deficit hyperactivity disorder, 1029, 1064, 1070–1074, 1086–1095
clonidine with, 1116–1117
Methylphenidate SR, 1064, 1088–1089, 1090
Metoprolol, drug interactions with, 1242
Mic-Key device, 1330, 1428–1429
Microcephaly, 1561–1562
Micro-orchidism, 820
Midazolam, 1529, 1535
Middle ear disease, in cleft lip and palate, 1495
Midgut volvulus. See *Malrotation and midgut volvulus.*
Midsystolic cardiac murmur, classification of, 109
Minaprine, 1168
Mirtazapine, 1164, 1168
Mitral area, in cardiac murmur evaluation, 112–113
Moclobemide, 1168
Molindone, 1206
in conduct disorders and aggression, 1214
studies of, 1211
Molluscum contagiosum, 1443
Monoamine oxidase inhibitors, drug interactions with, 1194, 1238, 1242, 1245, 1250, 1256
novel/atypical, 1165, 1168
Monoparesis, clinical approach to, 159–160
Monorchidism and anorchidism, 819–820
Monteggia fracture, 1520
Mood depressive disorder, selective serotonin reuptake inhibitors in, 1139–1140
Mood disorders, antipsychotics in, 1213
Mood stabilizers and anticonvulsants, **1173–1186**
in bipolar disorders, 1179–1182
carbamazepine, 1177–1178
in conduct disorder, 1182
drug interactions with, 1175, 1176, 1178, 1254
future mood stabilizers, 1276
gabapentin, 1178
lamotrigine, 1178–1179
lithium carbonate, 1173–1175

in mental retardation with aggressive behavior, 1182–1183
valproate, 1175–1177
Morphine, for postoperative analgesia, 1533
Motion, active and passive, in hand evaluation, 1508
Motor control, organization of, 145–147
Motor development, milestones in, 151
Motor dysfunction, management of, 164–165
Motor unit, and causes of weakness/clumsiness, 146
Mucous fistula, 1431
Multidisciplinary process, in neonatal risk assessment, 660
Multiple glomangiomas, 1474
Muscle, and causes of weakness/clumsiness, 147
of hand, 1508–1509
Muscle group weakness, clinical approach to, 159–160
Musculoskeletal complications of cancer treatment, 1644–1645
Mycobacterial lymphadenopathy/lymphadenitis, 880–881, 901–902
Mycobacterium turberculosis, 880–881, 901, 902
Myelocystocele, terminal, 1571–1572, 1573
Myelomeningocele, 1562–1565
Myopathies, proximal weakness with, 161

Nailbed injuries, 838, 1517–1518
Naloxone, with neonatal cardiopulmonary resuscitation, 594–595
Narcotics, 1529, 1533
Nasal deformities, in cleft lip and palate, residual, 1495
Nasolacrimal duct obstruction, congenital, 1002
Natal teeth, 1585
National Center for Health Statistics, violence data from, 270
National Crime Survey, violence data from, 271
National Institutes of Health, psychopharmacology research and, 1270–1273
National Wilms' Tumor Study Group, 1307, 1309–1311
National Youth Survey, violence data from, 270–271
Nausea, postoperative, management of, 1534
Neck lesions. See *Head and neck lesions.*
Neck pain, with spinal sports injuries, 224
Neck wounds, suturing, 838
Necrotizing enterocolitis, 1299
in intensive care nursery graduate, 1336–1337
neonatal surgery for, 609
Necrotizing facsciitis, omphalitis versus, 793
Neer test (impingement sign), 1602, 1603
Nefazodone, 1161, 1199
drug interactions with, 1250, 1255
Neonatal Arousal Scale, 835
Neonatal intensive care unit, bereavement program of, 697
codes for, 624–625
Neonatal intensive care unit graduate, 1347–1349
abdominal wall defects in, 1343–1344
anorectal malformations in, 1339–1342
biliary atresia in, 1342–1343
caring for, **701–712, 1327–1352**
chronic lung disease in, 86–89
congenital diaphragmatic hernia in, 1347–1349
cryptorchidism in, 1347
developmental care of, 80–81
discharge of, guidelines for, 80
ECMO survivors, 1349–1350
esophageal atresia and tracheoesophageal fistula in, 1335–1336
gastroesophageal reflux disease in, 1333–1335
growth of, 81–84
guidelines for, 80
hearing assessment of, 96
Hirschsprung's disease in, 1338–1339
history of perinatal course, 80
home monitoring of, 89
inguinal hernias and hydroceles in, 1345–1347
malrotation in, 1337–1338
management of, history and physical assessment in, **79–104**
necrotizing enterocolitis in, 1336–1337
neurologic assessment of, 89–95
nutrition in, 84–86, 1327–1329
scars of, 96–97
stomas in, 1329–1333
technology-dependent, management at home, 708–710
throacotomy and lung resections in, 1349
umbilical disorders in, 1344–1345
visual assessment of, 95–96
Neonatal surgery, advances in, **605–617**
biliary atresia, 615–616
congenital diaphragmatic hernia, 613–614
duodenal atresia, 607–608
esophageal atresia, 606
Hirschsprung's disease, 612–613

Neonatal surgery *(Continued)*
imperforate anus, 611–612
inguinal hernia, 614–615
midgut volvulus, 608–609
necrotizing enterocolitis, 609
pyloric stenosis, 607
short bowel syndrome, 610–611
tracheoesophageal fistula, 606
Neonatal teeth, 1585
Neonates, acute respiratory failure in, ventilation of, **475–509.** See also *Respiratory failure.*
non-critically ill, CPT codes for, 624
persistent pulmonary hypertension of, inhaled nitric oxide for, 535–537
physical examination of, 2–6
Neonatology, charges in, 622–624
CPT coding for, process of, 623
disease management in, **651–672**
model of, 651–653
outcome measures in, 661–663
application of, 663–664
clinical "outcomes"/health status, 662
patient/parent satisfaction, 662–663
utilization, 662
risk assessment in, 653–661
developing model, 656–658
guidelines for, 658–661
statistical analysis of, 657
future financial shock in, **619–633**
intensive care, CPT codes for, 624
reimbursement for, future of, 631–632
Medicare, 626
using RBRVS charges for, 625
reimbursement for, future of, 631–632
in managed care, 626–629
capitation, 628–629
case rates, 628
discounted fee-for-service, 627
per diem, 627
scenario of, 629–631
Nephrotoxicity, from cancer treatment, 1646
Nerve blocks, in hand disorders, 1513–1515
in postoperative pain management, 1534
regional, 1529
Nerve injuries, of hand, 1518
Neuroblastoma, 1302
clinical presentation and evaluation, 1304–1305
complications, prognosis, and outcomes, 1306–1307
epidemiology, 1303–1304
etiology and pathology, 1302–1303
historical perspective, 1302
staging, 1305–1306
treatment, 1306
Neuroleptic drugs, drug interactions with, 1238, 1250–1252, 1253
side effects of, 1028
Neurologically impaired patients, abdominal pain evaluation in, 763, 765–766
Neurologic assessment, in hand disorders, 1509–1510
of neonatal intensive care unit graduate, 89–95
cerebral palsy, 91, 93–94
head growth, 91
history in, 91
hydrocephalus, 90
hypoxic-ischemic encephalopathy, 90
intracranial hemorrhage, 90
periventricular leukomalacia, 91
reflexes, 93
seizures, 89–90
sonography for, 91
in severe neurologic impairment, 128–129, 135–137
Neurologic deficits, irreversible, identification of, 144
Neurologic impairment, catergorization by pathophysiologic characteristics, 122
evaluation of, theoretical framework for, 122
severe, **121–142**
acute illness in, 137–139
dysmorphic features in, 133
history of, 123–129
behavior, 129
developmental status and progress, 124–127
feeding and nutrition, 128
general, 123
information sought in, 125–126
neurologic, 128–129
social, 127–128
physical examination in, 130–137
cutaneous manifestations, 134
dysmorphology, 130–134
findings from, 131–132
general, 130
neurologic, 134–137
orthopedic, 137–138
Neuromuscular junction, and causes of weakness/clumsiness, 147
Neuropsychiatric effects of selective serotonin reuptake inhibitors, 1141, 1142–1143
Neurosurgical disorders, **1539–1578**
craniospinal dysraphism, 1562–1574
craniosynostosis and abnormally shaped head, 1545, 1548–1562
macrocrania, 1539–1545
Nevi, congenital nevomelanocytic, surgical management, 1447–1449

spider, 1471
Nevus flammeus neonatorum, hemangioma versus, 1463–1464
Nevus sebaceus, surgical management, 1443, 1446
Nevus sebaceus syndrome, 1446
Newborn asphyxiating thoracic dystrophy, 866
Newborns. See *Neonates.*
Niacin deficiency, 251
Nightmares, in children witnessing violence, 358
Nissen fundoplication, 1334, 1335
Nitric oxide, L-arginine pathway of, 533
effect on surfactant, 562–565
inhaled, **531–548**
for acute respiratory distress syndrome, 539–540
for congenital heart disease, 537–539, 544
dosing of, 543–545
for persistent pulmonary hypertension of newborn, 535–537, 544
physiologic response to, magnitude of, 543
safety of, 541–543
side effects of, 542
studies of, 536
for surfactant deficiency, 541
use of, rationale for, 533–535
mechanism of action of, 563
pathophysiologic actions of, 532
physiologic actions of, 531–532
with ventilation, in acute respiratory failure in newborns, 496–497
Nitric oxide synthase, in pyloric stenosis, 739–740
N-Myc amplification, in neuroblastoma, 1305
Nonsteroidal anti-inflammatory drugs, drug interactions with, 1253
in endometriosis, 1683
Noradrenergic neurons, 1101
Norepinephrine reuptake inhibitors, combined serotonin and, 1167
Nortriptyline, 1125. See also *Antidepressants, tricyclic.*
in anxiety disorders, 1195
in attention-deficit hyperactivity disorder, 1126
NSAIDs, drug interactions with, 1253
in endometriosis, 1683
Nutcracker phenomenon, 825
Nutrition. See also *Undernutrition.*
deficiencies, physical findings in, **243–258**
protein-energy malnutrition, 243–246
by system, 244
history, in severe neurologic impairment, 128
for intensive care nursery graduate, enteral nutrition, 1327–1328
parenteral nutrition, 1328–1329
in neonatal intensive care unit graduate, 84–86
for transplant recipients, 1407–1408

Obsessive-compulsive disorder, drug treatment of, 1030–1031
selective serotonin reuptake inhibitors, 1138–1139
tricyclic antidepressants, 1128
Occipital plagiocephaly, 1555–1556, 1559–1561
Occlusion, dental, 1590–1592
in exotropia, 1001
Ocular tumors, 1007–1008
OKT3, 1402
Olanzapine, 1206, 1207
in autistic disorder, 1215
in schizophrenia, 1212–1213
use of, 1223
Oligomenorrhea, 1680
Olive (pyloric) tumor, 741
Omeprazole, drug interactions with, 1249
Omphalitis, 793, 1344–1345
Omphaloceles, 1343–1344
Onychomycosis, 1441–1442
Operation on placental support (OOPS), 603
Ophthalmology, **993–1012**
care of transplant recipients, 1412
common signs and symptoms, 994–995
detection of disorders, 1009–1010
injuries, 1009
nonstrabismus conditions, aniridia, 1005
cataracts, 1005–1006
congenital nasolacrimal duct obstruction, 1002
congenital ptosis, 1003
infantile glaucoma, 1003–1005
strabismus conditions, definitions, 995–996
esodeviations, 997–1000
exodeviations, 1000–1002
pseudoesotropia, 996
tumors, 1007–1008
visual development, normal and abnormal, 993–994
Oppositional defiance, attention-deficit hyperactivity disorder with, 1057–1058
Oral cavity wounds, suturing, 838
Oral complications of cancer treatment, 1641–1642
Oral contraceptives, in dysfunctional uterine bleeding, 1679
in endometriosis, 1681–1682

Oral contraceptives *(Continued)*
health benefits of, 1677
medical issues in therapy with, 1675, 1677
in oligomenorrhea and polycystic ovary syndrome, 1680
in osteoporosis, 1675
patient dose and symptom diary for, 1678
pill selection, 1676–1677
side effects, managed with vitamin B_6 supplementation, 1677, 1679
Oral habits, orthodontics and, 1592–1594
Oral rehydration solutions, 726–727
Orchidopexy, 1347
Orchitis, 824
Organoid nevus, 1443
Organ transplantation. See *Transplantation, solid organ.*
Orthodontics, 1590–1592
Orthopedics, **943–971**
conditions not requiring immediate surgery, adolescent idiopathic scoliosis, 954–957
back pain, 957–959
cerebral palsy, 952–954
developmental dysplasia of hip in infant, 948–952
conditions rarely requiring referral or treatment, idiopathic toe walking, 960–961
Osgood-Schlatter disease, 966–967
rotational problems, 961–966
transient hip synovitis, 959–960
conditions requiring urgent referral, 945
slipped capital femoral epiphysis, 945–948
decision for surgery in, 944
diagnosis before referral for treatment, 943–944
Orthophoria, 995
Orthoptics, in exotropia, 1001
Ortolani test, 949
Osgood-Schlatter disease, 966–967
of knee, 235, 1621–1622
Osteochondritis dissecans, of elbow, 1612–1613
of knee, 235, 1628–1629, 1630
Osteonecrosis of hip, 951
Osteoporosis, prevention and treatment, 1675
Osteoradionecrosis, 1642
Ostomies. See *Stomas.*
Otitis media, tympanostomy with tube insertion for, 978–979
Otolaryngology, **973–991**
care of child with tracheostomy, 985–989
sinusitis, 982–985
tonsillectomy and adenoidectomy, 973–978
tympanostomy with tube insertion, 978–982
Otorrhea, tympanostomy tubes and, 981
Ovarian cysts, neonatal and pediatric, 1659–1661
Ovarian torsion, 1661
Ovarian tumors, 1661–1662

PACU, 1532
Pain, abdominal, recurrent, 1317–1321. See also *Abdominal diagnoses.*
back, 224, 957–959
knee, anterior, 1618–1620
management, 1532–1534
pelvic, 1680–1684
visceral, somatic, and referred, 732
Palmaris longus lacerations, 1516
PANDAS, 1031
Panic disorder, 1039, 1188
tricyclic antidepressants in, 1128–1129
Panner's disease, 1613, 1614
Panoramic radiographs, 1591–1592
Papillomaviral infection, genital warts from, 1665, 1666, 1667
Paraparesis, clinical approach to, 158–159
Paraphimosis, 806
Parental role, with adolescents with serious or sensitive issues, 190–192
Parenteral nutrition, for intensive care nursery graduate, 1328–1329
Parents, bereaved, attitudes toward, historical evolution of, 691–692
medical team and, 696–698
services for, 695
mental health of, in childhood psychiatric disorders, 30–31, 45
supporting violence prevention, 440
Parkes-Weber syndrome, 1450, 1471, 1476
Paronychia, 1522
Paroxetine. See also *Selective serotonin reuptake inhibitors.*
in anxiety disorders, 1192–1193
CYP-450 isozymes and, 1240
dosing and cost of, 1150, 1151
in mood depressive disorder, 1140
in obsessive-compulsive disorder, 1139
Patella, sports injuries to, examination for, 234
malalignment and instability, 1620–1621
Patent ductus arteriosus, 925–926
Patient-controlled analgesia, 1533–1534
Patient-triggered ventilation. See *Ventilation, patient-triggered.*
Pavlik harness, 951
Pectus carinatum, 865–866
Pectus excavatum, 863–865
Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), 1031

Pediatric Symptom Checklist, 1044
Pediatric Trauma Score, 834, 836
Peer relationships, in childhood psychiatric disorders, 33–34, 46
  support programs for suicide prevention/intervention, 374
PEG, 1421, 1429–1430
Pelvic inflammatory disease, 1684
  appendicitis and, 734
  beliefs and behaviors, 1685–1687
  clinical evaluation, 1684
  treatment, 1684–1685
Pelvis, fractures, 1616–1618
  pain, 1680–1684
  sports injuries, 231
Pemoline, in attention-deficit hyperactivity disorder, 1065, 1072, 1073, 1089, 1090
  hepatic failure and, 1093–1094
Penis, circumcision, recommendations, 802–803
    routine neonatal (and controversies), 801–802
    techniques, 803–805
  disorders, foreskin, 805–806
    shaft curvature and torsion, 809–810
    urethral meatus, 807–809
Pentalogy of Cantrell, 866
Peptic ulcer disease, 1299
Percutaneous endoscopic gastrostomy, 1421, 1429–1430
Percutaneous peripheral catheters, 1373–1375
Percutaneous polyethylene catheters, 1380–1381
Perineal problems. See *Rectal and perineal problems.*
Periodontal ligament, in tooth injuries, 1594, 1597, 1598
Periorbital hemangioma, 1007–1008
Peripheral intravenous central catheters, 1379–1380
Peripheral nerves, and causes of weakness/clumsiness, 146
  lesions of, muscle and sensory findings in, 160
Peripheral venous access, intraosseous catheters for, 1376–1377
  percutaneous peripheral catheters for, 1373–1375
  peripheral venous cutdown catheters for, 1375–1376
Peritoneum, visceral, embryology and anatomy, 729
Periventricular leukomalacia, 91
Perphenazine, 1206
Persistent pulmonary hypertension of the newborn, inhaled nitric oxide for, 535–537
Personality disorders, antipsychotics in, 1216–1217
Perthes' disease, 960
Pets, organ transplantation and, 1414
Peutz-Jeghers syndrome, 1296, 1368
Pezzer gastrostomy tube, 1330, 1426
Phakomatosis pigmentovascularis, 1471
Pharmacodynamics, 1023–1024
Pharyngeal flap, 1494
Phenelzine, 1165
Phenobarbital, drug interactions with, 1243, 1245, 1252
Phenothiazines, drug interactions with, 1246, 1250
Phenytoin, drug interactions with, 1242
Phimosis, 805
Phobias, 1188
Physeal fractures, 1519
Physical abuse, evaluation for, **203–217**
  blunt abdominal trauma, 210–211
  cutaneous trauma, 207–209
  falls and skeletal trauma, 205–206
  general considerations, 204–205
  head injury, 209–210
Physical environment, in suicide, 373
Physical examination, developmental status and, **1–23**
    adolescent, 19–22
    infant, 6–10
    newborn, 2–6
    school age child, 16–19
    toddler, 10–16
  in febrile infant, 66–75
  of neonatal intensive care unit graduate, **79–104**
  for sexual abuse, 212–215
  of skin, 50–54
Physical illness, in adolescent suicide, 371
Physicians, reimbursement of, history of, 620–622
Pierre Robin syndrome, 1482
Pilonidal disease of umbilicus, 797
Pilonidal sinus, 1368–1369
Pimozide, side effects of, 1221
  studies of, 1211
  in tic disorder, 1216
Pityriasis rosea, diagnosis of, 56–59
Pivot shift test, 1625, 1626
Placental support, operation on (OOPS), 603
Plagiocephaly, clinical presentation, 1554–1556, 1559–1560
  diagnostic studies, 1556–1560
  treatment, 1560–1561
Plastic baggy sign, 778
Plastic surgery, **1479–1506**
  breast surgery in adolescents, 1496–1502
  for cleft lip and palate, 1479–1496
  for scars, 1502–1503
  tattoo removal, 1503
  for torn earlobes, 1503

Play, in children witnessing violence, 358
Pleural disease, 867–869
Pleurodesis, 867–868
Plunging ranula, 898
Pneumocystis carinii pneumonia, in organ transplantation, 1406, 1407
Pneumonia, surfactant for, 557–559
Pneumonitis, from cancer treatment, 1644
Pneumoperitoneum, intraoperative diagnostic, 785
Pneumothorax, 867–868
  from intravenous catheters, 1385, 1388
Podofilox, 1442
Podophyllin, 1442
Poland's syndrome, 866, 1496
Police gatekeepers, for suicide prevention/intervention, 375
Polycystic ovary syndrome, 1680
Polyethylene catheters, percutaneous, 1380–1381
Polymastia, 1496, 1500
Polyorchidism, 820
Polyps, colonic bleeding from, 1300
  rectal, 1367–1368
  umbilical, 795
Polysomnography, multichannel, 975
Polytetrafluoroethylene grafts, in cardiac surgery, 917–918
Polythelia, 1496, 1500
Ports, implantable access, 1383, 1388
Port-wine stains, 1449–1451, 1470–1471
Positional molding, 1555–1556, 1559–1561
Postanesthesia care unit, 1532
Posterior cruciate ligament injuries, 1625, 1627, 1628
Posterior sagittal anorectoplasty, 1339, 1340–1341
Posterior sagittal anorectovaginourethroplasty, 1339, 1340–1341
Post-transplantation lymphoproliferative disorder, 1405, 1407
Post-traumatic stress disorder, 1039, 1188
  alpha–2 adrenergic agonists in, 1109, 1114
  in children witnessing violence, 359
  diagnostic criteria for, 360
  violence and, **341–353**
    assessment of, 345–347
    comorbidity and differential diagnosis of, 345–346
    context of evaluation of, 346–347
    developmental perspectives on, 343–345
    DSM-IV criteria for, 342
    exposure prevalence and, 343
    family system perspectives on, 347–348
    prevention and intervention for, 349–350
    treatment of, 348
Postural patterns, in severe neurologic impairment, 135–136
Potassium hydroxide (KOH), in skin evaluation, 55
Pouch management, for intestinal ostomies, 1433–1434
Poverty, in childhood psychiatric disorders, 35–36, 47
Preauricular pits, sinuses, and cysts, 895–896
Prednisolone, for hemangiomas, 1467
Pregnancy, cancer treatment complications of, 1648–1649
  in former cardiac surgery patient, 925
Premature atrial contractions, 911
Premature death, as consequence of violence, 333–334
Premature infants, early intervention system for, 706–708
  management of, history and physical examination in, 79–104. See also *Neonatal intensive care unit graduate.*
  normal, caring for, 702–705
  state control of, 703
Premature ventricular contractions, 912
Prematurity, anesthesia and, 1536
Preparticipation sports evaluation, 1633
Preventive dentistry, 1589–1590, 1598
Primary care pediatricians, psychosocial aspects of child abuse for, **391–402**
Prisms, in exotropia, 1000–1001
Privacy, for adolescents with serious or sensitive issues, 190–192
Problem-solving skills, in risk and resiliency for violence, 294
Proboscoid umbilical hernias, 797
Processus vaginalis, 774
Prochlorperazine, 1209
Promethazine, 1267
Propofol, 1528–1529, 1535
Propoxyphene, drug interactions with, 1246
Propranolol, drug interactions with, 1242, 1252
  extrapyramidal side effects treated with, 1220
Prosthetic heart valves, 915–917
Prosthetic patch materials, 917–918
Protein binding, selective serotonin reuptake inhibitors and, 1146
Protein-calorie malnutrition, definition of, 245
Protein-energy malnutrition, definition of, 245
  physical findings in, 243–246
Proteus syndrome, 1475–1476
Proximal humerus fractures, 1610–1612
Pseudoesotropia, 996

Psychiatric disorders, in adolescent suicide, 369
diagnosis of, historical clues to, **25–48**
assessment of severity, 38–39
interviewing, 26–27
screening questionnaires, 39–41
psychosocial questions for, 45–48
history taking in, 27–38
activity, 34–35
emotional health, 35
family, 28–31
injury, 36
peer relationships, 33–34
poverty, 35–36
risk-taking behavior, 37
school, 31–33
substance abuse, 36–37
suicide, 37–38
recognition and management of, **1037–1052**
anxiety disorders, 1039–1040
approaches to indentification, 1042–1044
attention-deficit hyperactivity disorder, 1038–1039
background, 1037–1038
comprehensive treatment planning, 1045–1049
conduct disorder, 1041–1042
consultation with pediatric psychopharmacologist, 1049–1050
depression, 1040–1041
future approaches to, 1273–1275
severity assessment, 1044–1045
substance-abuse disorders, 1041
risk and protective factors for, 40, 1045
symptoms of, 1026, 1044, 1045
Psychiatry, child and adolescent, future of, 1265–1266
Psychological factors in adolescent suicide, 371
Psychometric tests, in attention-deficit hyperactivity disorder, 1078
Psychopharmacologist, consultation with, 1049–1050
Psychopharmacology, alpha–2 adrenergic agonists, **1099–1122**
antidepressants, new, **1137–1171**
selective serotonin reuptake inhibitors, **1137–1155**
tricyclic, **1123–1135**
antipsychotics, **1205–1232**
in anxiety disorders, **1187–1204**
in attention-deficit hyperactivity disorder, 1029, **1053–1083**
in bipolar disorder, 1030
clinical evaluation in, 1025–1027
consent for treatment, 1027–1028
developmental issues and, **1021–1035**
diagnosis in, 1026
drug-drug interactions, **1233–1264**
drugs most prescribed to children "off label," 1267
evaluation for, 1025–1027, 1042–1044
future of, **1265–1278**
gender differences in, 1023
government efforts to increase information on, 1266–1273
individuality of child and, 1031
in major depressive disorder, 1030
medication side effects and age, 1028
mood stabilizers and anticonvulsants, **1173–1186**
in obsessive-compulsive disorder and PANDAS, 1030–1031
pediatric, as developing field, 1024
pharmacokinetics, pharmacodynamics, and medication dosing, 1021–1024
timing for treatment with medication, 1027
Psychosis, drug treatment of. See *Antipsychotics.*
Psychosocial interview, with adolescents with serious or sensitive issues, 194–199
Psychosocial stressors/precipitants, in suicide, 372
Psychostimulants, **1085–1098**
in attention-deficit hyperactivity disorder, 1029
adverse effects and management, 1073–1075, 1093–1096
age groups for, 1070–1073
comparison/contrast of, Adderall, 1087–1088
methylphenidate and dextroamphetamine, 1086–1087
other long-acting psychostimulants, 1088–1089
dosing and assessing response to, 1089–1092
follow-up visits for titration, 1075
initial therapy, 1070
myths about, 1063, 1066–1067
nonresponders to, 1075–1076
predicting response to, 1092–1093
drug interactions with, 1236–1237, 1238, 1252, 1255
historical perspective, 1085–1086
questions about, 1086
PTFE grafts, in cardiac surgery, 917–918
Ptosis, congenital, 1003
Pubarche, 1674
Puberty, disorders associated with, 1673–1680
Pubic hair development, 1674
Pulmonary area, in pediatric cardiac murmur evaluation, 112–113

Pulmonary arterial stenosis, cardiac murmur and, 115–116
Pulmonary complications of cancer treatment, 1644
Pulmonary development, processes in, surfactant and, 575–578
Pulmonary edema, 1531–1532
Pulmonary flow cardiac murmur, 114–115
Pulmonary hemorrhage, 562, 872
Pulmonary hypertension, persistent, of newborn, inhaled nitric oxide for, 535–537
Pulmonary sequestration, 870–871
Pulmonic valve stenosis, 928–929
Punch biopsy, 1440
Punishment. See also *Corporal punishment.*
  cultural differences in, 416
Purposefulness, in risk and resiliency for violence, 294
Pyloric stenosis, 739
  clinical presentation and evaluation, characteristics, 730
    diagnostic studies, 742–743
    history, 740
    physical examination, 741–742
  complications of treatment, 744–745
  differential diagnosis, 743–744
  epidemiology, 740
  feeding issues, 745–746
  fluid therapy in, 725–726
  gastroesophageal reflux disease versus, 1334
  neonatal surgery for, advances in, 607
  origin, 739–740
  pathology, 740
  treatment, 744
Pyloromyotomy, 744
Pyogenic granuloma, hemangioma versus, 1464
Pyridoxine deficiency, 251–252

Q angle, 1619
Quadriplegia, clinical approach to, 158
Questionnaires, in psychosocial screening, 1043–1044
Quetiapine, 1206, 1207, 1223
Quinidine, drug interactions with, 1246, 1252

Rabies, treatment recommendations, 846
Radial artery cannulation, 1391
Radial sensory nerve block, 1515
Radiation therapy. See *Cancer, treatment complications.*
Radiography. See *Imaging.*
Ranula, 898
Rapport, with adolescents with serious or sensitive issues, 193–194
RBRVS approach, to neonatology charges, 623–624
Rebelliousness, in children witnessing violence, 358
Rectal and perineal problems, **1353–1371**
  anal fissures, 1366
  bleeding, 1299–1300
  cloacal anomalies, 1358–1364
  colorectal carcinoma, 1368
  ectopic anus, 1356–1358
  fistula-in-ano, 1365–1366
  imperforate anus, 1353–1356
  pilonidal sinus, 1368–1369
  polyps, 1367–1368
  prolapse, 1364–1365
  sacrococcygeal teratoma, 1369–1371
Rectal biopsy, in Hirschsprung's disease, 1290
Recurrent abdominal pain syndrome, clinical presentation and diagnostic workup, 1318, 1320
  definition, epidemiology, and incidence, 1317–1318
  etiology, 1318, 1319
  management, 1320–1321
Red eye, 995
Reflexes, assessment of, in neonatal intensive care unit graduate, 93
  primitive, in severe neurologic impairment, 135–136
Regional anesthetics, 1529
Regression, in children witnessing violence, 358
Rehydration solutions, oral, 726–727
Reimbursement of physicians, history of, 620–622
Relationship violence, among adolescents, prevention of, 444–445. See also *Dating violence.*
Reliability, in neonatal risk assessment, 657, 660
Renal complications of cancer treatment, 1646
Renal injuries, 857
Renal physiology, fluid therapy and, 720–722
Renal transplantation. See *Kidney transplantation.*
Reproducibility, in neonatal risk assessment, 660
Reproduction, cancer treatment effects on, 1647–1648
Rescue treatment, for acute respiratory failure in newborns, 491–494
  air leak syndrome, 491–492
  pre-extracorporeal membrane oxygenation, 492–493

Resiliency factors, for suicide, 372–373
for violence, **293–305**
community/neighborhood-level, 297–298, 301
conceptual and methodologic issues of, 293–295
family-level, 296–297, 301
individual-level, 295–296, 301
societal-level, 298–299, 301
Respiratory distress. See *Acute respiratory distress syndrome.*
Respiratory failure, acute, in newborns, pulmonary function tests in, 501–503
ventilation for, **475–509**
airway pressure and flow during, 483
extracorporeal membrane oxygenation, 499–501
high-frequency, 485–490
airway pressures in, 488
gas exchange principles, 485–488
prevention of lung injury and RDS in, 489–490
ventilators for, 486, 488–489
liquid, 497–499
negative extrathoracic pressure, 494–496
nitric oxide, 496–497
patient-triggered, 476–485
assist control, 479, 482
clinical trials in, 484
future developments in, 484
physiologic considerations, 476–477
pressure support, 482–484
proportional assist, 484–485
synchronous intermittent mandatory, 479
rescue treatment, 491–494
air leak syndromes, 491–492
before extracorporeal membrane oxygenation, 492–493
segmental flow-volume loops for, 483
impending, identification of, 144
Resuscitation, in gastrointestinal bleeding, 1296
Retention polyps, 1300
Retinoblastoma, 1008
Retinopathy of prematurity, 95
Retractile testis, 814
Rhabdomyosarcoma, 1008
Riboflavin deficiency, 250–251
Rifampin, drug interactions with, 1246, 1249
Risk-taking behavior, in childhood psychiatric disorders, 37, 47
Risperidone, 1206, 1207
in autistic disorder, 1215
clozapine interacting with, 1255
in mental retardation, 1215–1216
in schizophrenia, 1212
studies of, 1211
in tic disorders, 1216
use of, 1223
Risser sign, 955
Ritonavir, drug interactions with, 1246
Rotational problems, 961–966
Rotator cuff injuries, 1601–1605
Rotator cuff muscles, 1602
Rovsig's sign, 734
Running away, in children witnessing violence, 358

Sacral agenesis, 1572, 1574
Sacrococcygeal teratoma, 602, 1369–1371
Sadness, 1040
Saethre-Chotzen syndrome, 1549, 1550
Salicylic acid, 1442
Salivary glands, cancer treatment complications of, 1642
Salter-Harris fracture classification, 1519
Salter-Harris injury, 1610
Sandifer's syndrome, 1334
Sarcoidosis, 883
Scabies preparation, in skin evaluation, 56
Scalp wounds, suturing, 838
Scaphocephaly (dolichocephaly), 1552–1554
Scars, in neonatal intensive care unit graduate, 96–97
plastic surgery for, 1502–1503
Schizophrenia, antipsychotics in, 1209, 1212–1213
School, in childhood psychiatric disorders, 31–33
academic achievement, 31–32
attendance, 32–33, 46
psychosocial questions about, 45–46
dropping out of, in children witnessing violence, 358
performance in. See *Academic achievement/performance.*
refusal, tricyclic antidepressants in, 1129
in suicide, 373
School-age child, physical examination of, 16–19
School/community gatekeeper training programs, for suicide prevention/intervention, 374
Scoliosis, 861–863
adolescent idiopathic, 954–957
Scratch sign, 867
Scrotal examination, 815–817
Scrotal pathology, acute, 824–825
swelling, 821–824

Seatbelt injuries, 858
Sebaceous nevus, surgical management, 1443, 1446
Second heart sound, 107
Seizures, in neonatal intensive care unit graduate, 89–90
Seldinger technique, 1380–1381
Selective serotonin reuptake inhibitors, **1137–1155,** 1157–1158
  in anxiety disorders, 1140, 1190, 1192–1194
  in attention-deficit hyperactivity disorder, 1076–1077
  controlled clinical efficacy trials of, 1138–1140
  costs of, 1148, 1150–1151
  cytochrome P–450 inhibition and, 1146–1148, 1149
  dosing, 1150, 1151–1152
  drug interactions with, 1145–1148, 1194, 1237–1243, 1247, 1249, 1252, 1253, 1255
  FDA indications for, 1137
  in major depressive disorder, 1030, 1139–1140
  in obsessive-compulsive disorder, 1138–1139
  open trials of, 1140–1141
  pharmacokinetics, 1144–1145
  preliminary work-up for, 1151
  protein binding and, 1146
  untoward effects of, 1141, 1143, 1193–1194
    discontinuation syndrome, 1144
    gastrointestinal, 1141
    neuropsychiatric, 1142–1143
    overdose, 1143–1144
Selenium deficiency, 255
Separation anxiety, 1039
  pharmacologic treatment of, 1190
  tricyclic antidepressants in, 1129
Sepsis, complications in appendicitis, 737
  after splenectomy, 856–857
Serotonergic antidepressants, novel, 1166–1167
Serotonin and norepinephrine reuptake inhibitors, combined, 1167
Serotonin levels in suicide, 373
Serotonin reuptake inhibitors, selective. See *Selective serotonin reuptake inhibitors.*
Serotonin syndrome, 1143
Sertraline, 1267. See also *Selective serotonin reuptake inhibitors.*
  in anxiety disorders, 1193
  CYP–450 isozymes and, 1240
  dosing and cost of, 1150
  indications, 1137
  in obsessive-compulsive disorder, 1139
  in pregnancy and nursing mothers, 1143
Service delivery, in early intervention system, 707–708
Sever's disease, 1631, 1632
Sex, in neonatal risk assessment, 654
Sexual abuse, 418–419
  evaluation for, **203–217**
  innocent genital trauma versus, 1662–1665
  lichen sclerosis versus, 1671
  physical examination for, 212–215
  recognition of, 394
Sexuality, in adolescents, with serious or sensitive issues, 198–199
    violence prevention strategies with, 444
  in transplant recipients, 1411
Sexually transmitted disease, in adolescents, 312–314, 1684–1685
Sexual side effects of psychotropic drugs, 1028, 1143
Shaken-baby syndrome, evaluation for, 209–210
Shave biopsy, 1440
Shimada classification system, 1303
Shin splints, 238
Short bowel syndrome, neonatal surgery for, advances in, 610–611
Short gut syndrome, in necrotizing enterocolitis, 1337
Shoulder, sports injuries to, 227
  clavicle fractures, 1608–1610
  instability, 1605–1608
  proximal humerus fractures, 1610–1612
  rotator cuff, 1601–1605
Shunts, in hydrocephalus, 1542–1544
  infections of, 1543–1544
Silastic central venous catheters, 1381–1382
Silk glove sign, 778
Simple interrupted suture, 839
Sinding-Larsen-Johansson disease, of knee, 235, 1622
Single ventricle, and Fontan operation, 936–938
Sinuses, preauricular, 895–896
  thyroglossal duct, 896–897
  vitelline and urachal, 795
Sinusitis, 982
  clinical presentation, 982–983
  epidemiology, 982
  treatment, 983–985
Skeletal trauma, evaluation of, for physical abuse, 205–206
Skin, in children, systematic evaluation of, **49–63**
  dermatologic history, 49–50
  diagnostic procedures, 55–56
    potassium hydroxide (KOH), 55
    scabies preparation, 56

Wood's lamp examination, 55–56
difficult diagnoses, 56–62
granuloma annulare, 58–61
pityriasis rosea, 56–59
scabies, 58–59, 61–62
tinea capitis, 57–60
physical examination, 50–54
color, 54
configuration, 53
distribution, 54
primary lesions, 51–52
secondary lesions, 52–53
Skin biopsy, 1439–1441
Skin irritation, in gastrostomy, 1423
Sleep, disrupted, in infants witnessing violence, 358
Slipped capital femoral epiphysis, 945–948, 1615–1616, 1617
Small bowel obstruction, adhesive, 730, 761–762
Smoking, risk factors for, in adolescents, 310
Soave's endorectal pull-through procedure, 1288, 1292
Social competence, in risk and resiliency for violence, 294
Social factors, in adolescent suicide, 368–369, 372–373
Social history, in child abuse, 393
in severe neurologic impairment, 127–128
Social phobias, 1039, 1188
Sodium bicarbonate, in neonatal cardiopulmonary resuscitation, 595
Somatic symptoms, in children witnessing violence, 358
Spastic diplegia and hemiplegia, 953
Speech development, after cleft palate repair, 1493–1494
Spermatic cord structures, injury to, 1346
Spermatic cord torsion, 821–823
Sphincter pharyngoplasty, 1493
Spider telangiectasia, 1471
Spigelian hernia, 787
Spinal anesthesia, 1529
Spinal cord, and causes of weakness/clumsiness, 146
tethering, 1563–1565
Spinal dysraphism. See *Craniospinal dysraphism.*
Spine, chronic conditions of, 226
lipomas, 1565–1567
sports injuries, 223–226
examination for, 224–225
mechanisms of, 225
Spleen injuries, 855–857
Splenectomy, 1640
sepsis after, 856–857
Splints, intrinsic plus position for, 1517
Split cord malformations, 1569–1571
Sports injuries, **219–242, 1601–1635**
acute versus chronic, 220
age of child with, 222
locations of, 222
lower extremity, 231–238, 1616–1632
nonsports-related conditions versus, 220
preparticipation evaluation and, 1633
spine, 223–226
upper extremity, 227–230, 1601–1615
Sports participation, by former cardiac surgery patient, 922–923
Squeeze test, 1630
SSRIs. See *Selective serotonin reuptake inhibitors.*
Stamm gastrostomy, 1420–1421
Staphylococcus, in lymphadenopathy, 879
Steroids. See *Corticosteroids.*
Stickler syndrome, 1482
Still's cardiac murmur, vibratory, 114
Stimulants. See *Psychostimulants.*
Stomal granulomas, 989
Stomas, **1419–1435**
cervical esophagostomy, 1329–1330
gastostomy, 1330–1332
intestinal ostomies, 1332–1333, 1430–1434
Strabismus, 995
definitions, 995–996
esodeviations, 997–1000
exodeviations, 1000–1002
pseudoesotropia, 996
Streptococcus, autoimmune neuropsychiatric disorders and, 1031
in lymphadenopathy, 879
Streptococcus mutans, 1585–1586
Streptococcus pneumoniae, in empyema, 868
Stress, acute stress disorder, 1188
after trauma. See *Post-traumatic stress disorder.*
Stupor, definition of, 138
Sturge-Weber syndrome, 1450, 1470
Subclavian vein, location and anatomy, 1380
vascular access via, 1381, 1382, 1386–1387
Subcuticular suture, 842
Submucous cleft palate, 1494
Substance abuse, 1041. See also *Alcohol use; Drug abuse.*
in psychiatric disorders, 36–37, 47, 1023
Subungual hematomas, 1517–1518
Sucking, non-nutritive, orthodontics and, 1592–1593
Sudden death, in former cardiac surgery patient, 913
from methylphenidate with clonidine, 1116–1117
tricyclic antidepressants and, 1129–1130

Suicide, adolescent, 187, **365–380,** 421
biologic factors in, 371
empirical profiles of, 370
epidemiology of, 365–367
nonfatal, rates of, 368
risk factors for, 367–372
with serious or sensitive issues, 199
in childhood psychiatric disorders, 37–38, 47–48
among children and adolescents, rates of, 276
consequences of, 373
prevention and intervention strategies for, 374–376
risk and resiliency factors in, 372–373
selective serotonin reuptake inhibitors and, 1143, 1194
Sulfamethoxazole-trimethoprim, for *Pneumocystis carinii* pneumonia in organ transplantation, 1406
Sulfonylureas, drug interactions with, 1247
Sulpride, 1167
Suppression, ocular, 994
Supraclavicular systolic cardiac murmur, 116
Supraventricular arrhythmias, in former cardiac surgery patient, 911–912
Surfactant, for acute respiratory distress syndrome, 559–561
for chronic lung disease in premature infants, 574
clinical trials of, meta-analysis of, 578
composition, 550
for congenital diaphragmatic hernia, 561–562
for critically ill infants, odds of death after, 642–643, 646
deficiency of, inhaled nitric oxide for, 541
exogenous, effectiveness of, factors influencing, 549–552
future directions with, 565–566
and high-frequency ventilation, 552–554
in immune system modulation, 557
liquid ventilation and, 565
for meconium aspiration syndrome, 518–521, 554–556
metabolism, 551
nitric oxide and, 562–565
placebo-controlled trials of, 576–577
for pneumonia, 557–559
preparations of, 550
pulmonary development processes and, 575–578
for pulmonary hemorrhage, 562
replacement therapy with, **549–572**
for very low birthweight infants, economic impact of, 683–684
Suturing, in mild injuries, 837, 840
by anatomic location, 838
techniques illustrated, 839–842
Swelling, scrotal, acute, 821–824
Swenson's coloanal anastomosis, 1288, 1292
Sympathomimetics, drug interactions with, 1246, 1255
Synovitis, hip, transient, 959–960
Syringomyelia, 1563–1565
Systolic cardiac murmur, classification of, 108–109

Tachycardias, nodal, 911
Tacrolimus, in organ transplantation, 1396, 1398, 1399–1400
Tailor position for scrotal examination, 816
Tangential biopsy, 1440
Tattoo removal, 1503
Team approach, to former cardiac surgery patient, 908–909
Technology-dependent children, management at home, 708–710
Teeth. See also *Dental care; Dental problems.*
cancer treatment complications of, 1641–1642
development of, 1581, 1583–1585
trauma of, 1594–1598
Telangiectases, 1471–1472
Television viewing time, and academic achievement, 326
Temperature control, anesthesia and, 1531
Tendons, of hand, 1508–1509
Tension pneumothorax, 867
Teratomas, sacrococcygeal, 1369–1371
Terfenadine, drug interactions with, 1243
Terminal myelocystocele, 1571–1572, 1573
Testes, descent of, 814
undescended. See *Cryptorchidism.*
Testicular cancer, 818, 824
Testicular problems, **813–830**
cryptorchidism, 813–819, 1346, 1347
macro-orchidism, 820–821
micro-orchidism, 820
monorchidism and anorchidism, 819–820
polyorchidism and transverse testicular ectopia, 820
scrotal pathology, acute, 824–825
scrotal swelling, acute, 821–824
torsion, 781, 821–823
varicocele, 825–826
Tetanus, prophylaxis, 846
Tetralogy of Fallot, 931–933
TGF-α, in cleft lip and palate, 1483
Thal fundoplication, anterior, 1334–1335
Thelarche, 1674
Theophylline, drug interactions with, 1243, 1253

Theory, definition of, 282
levels of, 283
Thiamine deficiency, 250
Thiazide diuretics, drug interactions with, 1253
Thickened filum terminale, 1571, 1572
Thioridazine, 1206
in conduct disorders and aggression, 1214
in schizophrenia, 1209, 1212
studies of, 1211
Thiothixene, 1206
in schizophrenia, 1209, 1212
studies of, 1211
Third ventriculostomy, endoscopic, 1542
Thoracic pressure, negative, with ventilation, in acute respiratory failure in newborns, 494–496
Thoracic spine, sports injuries to, 224
Thoracotomy, 1349
Thorazine, 1208
Thromboembolism, valve prostheses and, 916
Thrombosis, catheter occlusion and, 1390
Thyroglossal duct cysts and sinuses, 896–897
Thyroid complications of cancer treatment, 1645
Tianeptine, 1167
Tibial torsion, 961–962, 964–965
Tic disorders, alpha–2 adrenergic agonists in, 1110, 1112, 1113–1114, 1117–1118
alpha–2 adrenoreceptor dysfunction in, 1103, 1108–1109
antipsychotics in, 1216
tricylic antidepressants in, 1128
Tics, psychostimulants and, 1074–1075, 1095–1096
Tinea capitis, diagnosis of, 57–60
Tobacco use, in adolescents, 310
Toddlers, physical examination of, 10–16
Toe walking, idiopathic, 960–961
Tongue thrusting, orthodontics and, 1593
Tonsillectomy, 973
clinical presentation for, 974
diagnostic studies before, 975
indications, 975–976
perioperative concerns in, 976
special circumstances, 976
Torsion, spermatic cord, 821–823
Torticollis, 899
Toupet fundoplication, posterior, 1334–1335
Tourette's syndrome/disorder, 1074–1075, 1095
alpha–2 adrenergic agonists in, 1100, 1112, 1113–1114
alpha–2 adrenoreceptor dysfunction in, 1103, 1108–1109
antipsychotics in, 1216
tricylic antidepressants in, 1128
Trace elements, deficiencies of, 254–255
Tracheitis, 989
Tracheoesophageal fistula, esophageal atresia and, 1335–1336
neonatal surgery for, 606
Tracheomalacia, 1336
Tracheostomy, care of child with, 985–986
complications, 989
follow-up care, 989
frequently asked questions, 987–989
medical equipment, 987
stoma care, 986–987
suctioning, 986
tracheostomy tie and tube, 986
Transforming growth factor alpha, in cleft lip and palate, 1483
Transplantation, solid organ, **1395–1418**
activity and exercise after, 1413
in adolescents, 1409–1410
graft-versus-host disease in, 1412
growth and development after, 1408–1411
health care maintenance in, 1411–1412
immunusuppression in, 1396
with cyclosporine, 1397
monitoring therapy, 1398–1400
primary care physician's perspective on, 1400
with tacrolimus, 1398
infectious complications of, 1403
immunizations and, 1406–1407
primary care physician's perspective on, 1407
specific microorganisms, 1403–1406
timing of, 1404
noncompliance in, 1410
number of transplants, 1396
nutrition in, 1407–1408
patient and family education for, 1413
pediatric transplant coordinator for, 1412
pets and, 1414
rejection of, 1400–1401
primary care physician's perspective on, 1402–1403
specific organs, 1401–1402
treatment of, 1402
return to school after, 1413–1414
survival rates, 1396–1397
Transposition of great arteries, 934–936
Transverse testicular ectopia, 820
Tranylcypromine, 1165
Trauma. See also *Injuries.*
dental, 1594
of permanent dentition, 1597–1598
of primary dentition, 1594–1597
genital, 1662–1665
hand, 1516–1521

Trauma. See also *Injuries. (Continued)*
injury severity and mortality, 836
late sequelae of, **853–859**
abdominal injury, 855–858
brain injury, 854–855
familial impact, 858
leading causes of death, 854
multisystem injury, 853–854
minor injuries, **831–851**
burns, 845–847
child abuse, 844
diagnosis, 833–836
dog bites, 845, 846
epidemiology, 831–833
foreign bodies, 847–848
head injury, 843–844
prevention, 841–843
prognosis, 840–841
wound management, 836–840
ocular, 1009
testicular or scrotal, 824
Travel, by former cardiac surgery patient, 924
Trazodone, 1160–1161
Tretinoin, 1443
Triazolam, drug interactions with, 1255
Tricuspid area, in pediatric cardiac murmur evaluation, 112–113
Tricyclic antidepressants. See *Antidepressants, tricyclic.*
Trifluoperazine, 1206
Trigonocephaly, 1554, 1555
Trihexyphenidyl, 1220
Triiodothyronine, in depression, 1166
Trimethoprim-sulfamethoxazole, for *Pneumocystis carinii* pneumonia in organ transplantation, 1406
Tryptophan, in depression, 1166
drug interactions with, 1243
Tuberculous cervical lymphadenopathy, 880–881
Tufted angioma, 1465
Tunica vaginalis, 774–775
Twin-to-twin transfusion, fetal surgery for, advances in, 602–603
Two-point discrimination testing, 1509–1510
Tympanic membrane perforation, 981–982
Tympanosclerosis, 982
Tympanostomy with tube insertion, complications of tubes, 981–982
indications, 978–979
long-term care and instructions after, 980
perioperative care, 980
postoperative evaluation, 980
preoperative evaluation, 979–980
Typhlitis, 764–765

Ulcerative colitis, 1300, 1301
Ulcers, from cutaneous hemangiomas, 1466
gastroduodenal, 1298–1299
Ulnar nerve block, 1515
Ultrasonography, in abdominal diagnoses, appendicitis, 735–736
intussusception, 748
pyloric stenosis, 743
of cleft lip and palate, 1486
Umbilical cord development, 792
Umbilical problems in children, **791–799,** 1344–1345
delayed stump separation, 796
embryology, 791–793
granuloma, 793–794
hernia, 796–797
omphalitis, 793
unusual, 797
urachal anomalies, 795–796
vitelline duct anomalies, 794–795
Umbilical vascular access, 1383, 1389
Undernutrition, definition of, 167
evaluation of, **167–185**
Uniform Crime Report, violence data from, 270
Unilateral coronal synostosis, 1554–1555, 1556, 1560
Upper extremity, sports injuries ro, elbow and forearm, 227–229, 1612–1615
shoulder, 227, 1601–1612
wrist and hand, 229–230
Upper gastrointestinal bleeding, 1296–1299
Upper GI studies, in gastroesophageal reflux, 1334
in malrotation and midgut volvulus, 756–757
in pyloric stenosis, 742
Upper respiratory tract infections, anesthesia and, 1535
sinusitis in, 982
Urachal anomalies, 795–796
Urachal cysts and sinuses, 1345
Urea, 1443
Urethral meatus disorders, 807–809
Urinary tract infection, in neurologically impaired child, 139
Urinary tract obstruction, fetal surgery for, 600
Urokinase, 1329
Uterine bleeding, dysfunctional, treatment of, 1679–1680

VACTERL complex, 1335, 1339, 1353–1354
Validity, in neonatal risk assessment, 657, 660
Valproate, 1175–1177
in bipolar disorders, 1180–1181

in mental retardation with aggressive behavior, 1183
toxicity, 1028
Valproic acid, drug interactions with, 1247
Valvotomy, 915
Variceal hemorrhage, 1299
Varicella-zoster virus, in organ transplantation, 1406, 1407
Varicoceles, 825–826
Vascular access. See *Intravenous access.*
Vascular anomalies, **1455–1477**
malformations, 1470
arteriovenous, 1474–1475
capillary, 1449–1451, 1470–1471
classification, 1470
complex-combined, 1475–1476
hemangiomas versus, 1464
lymphatic, 1472–1473
telangiectases, 1471–1472
venous, 1473–1474
nomenclature and nosology, 1455–1456
tumors, differential diagnosis, 1463–1465
hemangiomas, 1456–1462
kaposiform hemangioendothelioma or Kasabach-Merritt phenomenon, 1462–1463
management of hemangiomas and their potential complications, 1465–1470
radiologic evaluation, 1465
Vascular examination, in hand disorders, 1510–1511
Vascular injuries, of hand, 1518
Vasculitis of scrotal wall, 824–825
Vasodilators, macroselective versus microselective, 534–535
Veaux-Wardill-Kilner push-back palatoplasty, 1492
Velopharyngeal incompetence/insufficiency, 1493–1494
Venlafaxine, 1162–1163
Venous access, central, 1379–1384
peripheral, 1373–1379
Venous hum cardiac murmur, 117
Venous malformations, 1473–1474
Ventilation, for acute respiratory failure in newborns, **475–509.** See also *Respiratory failure.*
high-frequency, surfactant and, 552–554
liquid, in acute respiratory failure in newborns, 497–499
surfactant and, 565
neonatal, indications for, 592
patient-triggered, for acute respiratory failure in newborns, 476–485
assist control, 479, 482
clinical trials in, 484
future developments in, 484
physiologic considerations, 476–477
pressure support, 482–484
proportional assist, 484–485
synchronous intermittent mandatory, 479
Ventricular disorders, in former cardiac surgery patient, 918
arrhythmias, 912–913
single ventricle and Fontan operation, 936–938
ventricular septal defects, 927–928
Ventricular shunting, in hydrocephalus, 1542–1544
Ventriculitis, in neurologically impaired child, 139
Ventriculomegaly, 1541, 1543
Verapamil, drug interactions with, 1247
Vertical mattress suture, 841
Very low birthweight infants, antenatal management, 680–681
developmental outcome in, **673–690**
review of studies on, 673–674
edge of viability in, 675
mortality in, 674–675
neonatal management, 681–683
postnatal management, 683
reducing morbidity in, 680–683
school-age outcome in, 678–680
stable morbidity in, 676
variable impairment with, 676–678
surfactant for, economic impact of, 683–684
Vesicoumbilical fistula, 79
Vibratory Still's cardiac murmur, 114
Victims, in childhood psychiatric disorders, 33–34, 46
Violence, adolescent, alcohol intake and, 308
and associated high-risk health behavior, **307–317**
community-based model of, 463
drug abuse and, 311
sexual behavior and, 313
smoking and, 310
anticipatory guidance, **439–448**
primary prevention strategies, 440–442
for adolescents, 443–445
four-year-old visit, 441–442
infant and toddler visits, 441
latency age visit, 442
newborn/two-week visit, 440
teenager visit, 442
ten-month visit, 441
application of public health model to, 286
against children and adolescents, 271–276
firearm homicide, 274–275
homicide rates by age, gender, and race, 271–274

Violence *(Continued)*
international comparison for homicide, 275–276
international perspectives, **415–426**
interstate homicide rates, 274–275
suicide rates, 276
children as perpetrators, 276–277
children witnessing, **355–364**
definition of, 356
effects of, 359–360
epidemiology of, 356–357
impact of, factors mediating, 358–359
interventions for, 360–361
violence in, 359
community intervention and prevention of, **459–467**
Harlem Hospital injury prevention program, 464–465
information resources for, 465
public health approach, 460–464
community context, 462–464
problem definition, 460–462
concepts of, 282
consequences of, **333–340**
premature death, 333–334
violence recidivism, 334–336
violent criminality, 336–338
cycle of, in adolescent suicide, 371–372
hypothesis concerning, 288
data on, reliability of, 271
sources of, 270–271
dating. See *Dating violence.*
definition of, 270
in emergency department, **449–457**
exposure to, developmental perspectives on, 343–345
individual-level resilience and for, 300–301
interventions for, 449–450
media, **319–331**
adverse impact of, prevention of, 329
children's choice of, by age and sex, 322–323
consequences of, 325–329
academic performance, 327–328
aggressive behavior, 325–326, 328
alcohol and cigarette consumption, 327
current analysis of, 319–323
definition of, 320
demographics and attributes of perpetrators and targets, 321
industry averages of, 320
movies, 324
music, 324
music videos, 324
outcomes of exposure to, impact of contextual factors in, 322
television, 323–324
video games, 324
vulnerability to, prediction of, 328–329
model of, public health approach to, 285–288
neighborhood-level resilience and risk for, 297–298, 300–301
perpetrators of, psychosocial interventions for, 450–451
and post-traumatic stress disorder, **341–353**
prevention and intervention for, integration into medical practice, 447
recidivism, as consequence of violence, 334–336
risk and resiliency factors for, 269–270, **293–305,** 300
community/neighborhood-level, 297–298
conceptual and methodologic issues of, 293–295
family-level, 296–297
individual-level, 295–296
societal-level, 298–299, 300–301
statistics on, **269–280**
theoretical frameworks of, **281–291**
importance in addressing violence, 282–283
theory, 282–283
victims of, psychosocial interventions for, 450
youth, prevention of, public health approach to, 287
Violent criminality, as consequence of violence, 336–338
Viral infections, in lymphadenopathy, 877–879
in organ transplantation, 1403–1406, 1407
Virginal hypertrophy, 1499
Vision, cancer treatment complications of, 1640–1641
decreased, 994–995
development, normal and abnormal, 993–994
screening, 1009–1010
Visual assessment, of neonatal intensive care unit graduate, 95–96
Visual impairment, in very low birthweight infants, 676
Vitamin B_6, oral contraceptive side effects and, 1677, 1679
Vitamin deficiencies, fat-soluble, 248–250
vitamin A, 248
vitamin B, 250–253
vitamin C, 253–254
vitamin D, 249
vitamin E, 249
vitamin K, 249–250
water-soluble, 250–254

Vitelline duct anomalies, 794–795
Volume expansion, with neonatal cardiopulmonary resuscitation, 595
Volvulus, midgut. See *Malrotation and midgut volvulus.*

WAGR syndrome, 1308
War, child maltreatment in, 421–423
Warfarin, drug interactions with, 1243
  valve prostheses and, 916–917
Warts, 1442
  genital, 1665–1667
Water, total body, 720–721
Weakness/clumsiness, approach to, **143–166**
  causes by system, 146–147
  clinical, 147–165
    history, 147–153
      age of onset, 151–152
      localization of, 152–153
      timing of development, 149–151
    management of, 164–165
    physical examination, 153–163
      assessment of tone, 154
      associated sensory findings, 161–162
      central versus peripheral, 156
      conversion disorder, 163
      coordination, 162–163
      diplegia, 158–159
      distribution of weakness, 156
      findings with central lesions, 157–158
      findings with peripheral lesions, 160–161
      hemiparesis, 158
      isolated muscle groups, 159–160
      monoparesis, 159–160
      paraparesis, 158–159
      patterns of distribution, 158–160
      quadriplegia, 158
      quantification of, 154–155
Weapon carrying, adolescent, alcohol intake and, 308
  drug abuse and, 311–312
  sexual behavior and, 313–314
  violence prevention strategies for, 447
Weight, reduced, in failure to thrive, 178
Weight bearing, with lower extremity injury, 236
Whiplash shaken-baby syndrome, evaluation for, 209–210
White blood cells, in appendicitis, 735, 737
Wilms' tumor, clinical commentary, 1311, 1314
  clinical presentation and evaluation, 1308–1309
  complications, 1311
  differential diagnosis, 1310
  epidemiology, 1307–1308
  etiology and pathology, 1307
  historical perspective, 1307
  outcomes, 1310–1311
  staging, 1309–1310
  treatment, 1310
Wisconsin minor consent laws, 191
Withdrawal, in children witnessing violence, 358
Wood's lamp examination, of skin, 55
Wound management, in minor injuries, 836–840
  burns, 847
  dog bites, 845
Wrist, sports injuries to, 229–230
Wrist blocks, 1514–1515

Xeroderma pigmentosum, 1443
Xerostomia, 1642

Yale Observation Scale, of infant and child illness, 73

Zinc deficiency, 254